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  ABSTRACT 
 
Factor Va is a plasma protein that plays an important role in the regulation of blood 
coagulation by serving as the essential cofactor in thrombin generation via the 
prothrombinase complex. The procofactor, factor V, exists in two whole blood pools with 
75-80% found in plasma, and 20-25% stored in the α-granules of platelets. As compared 
to the plasma procofactor, platelet-derived factor V is physically and functionally 
distinct, and displays a more procoagulant phenotype. Despite these profound 
differences, platelet-derived factor V originates via endocytosis of the plasma-derived 
procofactor by megakaryocytes. Endocytosis is mediated by two receptors: an 
unidentified, specific factor V receptor, and low density lipoprotein (LDL) receptor 
related protein-1 (LRP-1), a ubiquitous receptor that plays a role in endocytosis of 
proteins targeted for lysosomal degradation. These observations represent a novel role for 
LRP-1 in endocytosis of a protein that is functionally modified, and not targeted for 
lysosomal degradation. The goal of this study is to define the factor V regions involved in 
its interactions with the unidentified factor V receptor and LRP-1 expressed on 
megakaryocytes to begin to elucidate the molecular mechanisms regulating formation of 
the unique platelet-derived cofactor. Epitope mapping studies were performed using anti-
factor V monoclonal antibodies, E9 and anti-factor V #2. Previous observations indicated 
that these factor Va light chain antibodies inhibited endocytosis of factor V by 
megakaryocytes. However, subsequent analyses demonstrated that only E9 inhibited both 
factor V binding and endocytosis. Thus, it was used for these studies. Western blotting of 
factor V and Va suggested that E9 recognizes a conformation-dependent epitope, which 
precluded the use of conventional epitope mapping approaches used for linear epitopes. 
E9 had no effect on factor Va cofactor activity in a plasma-based clotting assay 
suggesting that it does not perturb factor Va’s interactions with the membrane surface or 
factor Xa. Cleavage of lipid-bound factor Va by factor Xa at Arg1765 was also not 
affected by the presence of E9 suggesting that the epitope is not directed against this 
cleavage site. When E9 was used to immunoprecipitate the factor Xa-generated light 
chain cleavage products, both the 48/46 and 30 kDa light chain fragments were captured. 
These observations were confirmed using a solid phase competition assay where factor 
Xa-cleaved factor Va inhibited binding of 
125
I-factor V to E9 as well as intact factor V or 
Va. Limited proteolysis of the factor Va light chain with trypsin or Asp-N, generated 
products that were no longer detectable in this assay. These combined observations 
suggest that the anti-factor V light chain antibody, E9, has an epitope that is 
conformation-dependent and extremely labile. Future directions and alternative 
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1.1 Overview of Hemostasis 
 
 Blood is a heterogeneous mixture of red blood cells, leukocytes, and platelets 
suspended in a fluid known as plasma that contains lipids, carbohydrates, salts, 
hormones, proteins, and gases (Williams and Nelson 1990). The components of blood 
serve a host of different functions, including oxygen delivery to tissues, protection 
against infectious agents, and transport of vitamins and nutrients throughout the body 
(Alper 1990; Erslev and Lichtman 1990). These physiological processes occur in a 
dynamic environment and therefore necessitate the fluidity of blood. In order for blood to 
be maintained in a fluid state, humans have evolved a mechanism that is initiated upon 
tissue injury; this process is known as hemostasis. During hemostasis, blood coagulation 
is initiated and terminated in a rapid and highly regulated manner allowing for the 
equilibrium between a procoagulant and anticoagulant state to be restored, thus 
preventing the event of uncontrolled bleeding or disseminated thrombosis following 
vascular damage. 
The sequence of events that occur during hemostasis following vascular damage 
can be divided into four separate but related stages: primary hemostasis, coagulation or 
secondary hemostasis, termination, and fibrinolysis. During primary hemostasis, blood 
vessel damage occurs disrupting the endothelial cells lining the blood vessel wall leading 
to the exposure of subendothelial proteins including collagen, fibronectin, fibrinogen, 
laminin and von Willebrand factor that are typically sequestered in the intact vasculature 
away from blood (Weiss, Baumgartner et al. 1978; Hindriks, Ijsseldijk et al. 1992; 
Beumer, MJ et al. 1994; Savage, Saldivar et al. 1996; Farndale, Sixma et al. 2004). 
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Platelets adhere to the damaged site through interactions with these subendothelial 
proteins via a number of integrins and glycoprotein (GP) receptors (Ruggeri, Bader et al. 
1982; Santoro 1986; Moroi, Jung et al. 1989; Tandon, Kralisz et al. 1989; Savage, 
Almus-Jacobs et al. 1998; Shen, Romo et al. 2000; Inoue, Suzuki-Inoue et al. 2006). The 
adhesion of platelets to collagen via its specific receptor leads to platelet activation. 
Activated platelets undergo a dramatic shape change due to cytoskeletal changes and 
release hemostatically-active α and dense granule components that are comprised of a 
number of different coagulation factors, including fibrinogen and factor V/Va (Jandrot-
Perrus, Lagrue et al. 1997; Polgar, Clemetson et al. 1997; Kehrel, Wierwille et al. 1998; 
Hartwig 2007). The activation of platelets also leads to a conformational change in 
GPIIb/IIIa (integrin αIIb/β3), which mediates platelet aggregation and platelet plug 
formation by bridging adjacent platelets to each other via fibrinogen. While platelet plug 
formation is sufficient to stop the loss of blood initially, the formed platelet plug must be 
stabilized by the formation of fibrin via blood coagulation to prevent rebleeding at the 
injury site.  
 Blood coagulation is initiated by the exposure of subendothelial cell-expressed 
tissue factor at the site of injury, which binds to plasma factor VIIa to form the extrinsic 
Xase complex, and in the presence of calcium activates factor X to factor Xa and factor 
IX to IXa (Nemerson 1988; Morrissey, Macik et al. 1993). Factor Xa, in turn, forms a 
complex with activated platelet released, membrane-bound platelet-derived factor V/Va 
to make a small amount of thrombin (Barton, Jackson et al. 1967; Walsh 1974; Mann, 
Nesheim et al. 1990). Thrombin activates factor VIII to VIIIa, which together with factor 
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IXa and calcium forms the intrinsic Xase complex to activate factor X to Xa thus further 
contributing to thrombin generation (Hemker and Kahn 1967; Hultin and Nemerson 
1978). Not only does thrombin effect cleavage of fibrinogen to fibrin (Bailey, Bettelheim 
et al. 1951; Doolittle 1973), it further propagates the response by activating plasma and 
platelet factor V to Va, and recruits more activated platelets to the growing thrombus 
(Figure 1.1).   
 Subsequent to formation of the fibrin clot, the coagulation response must be 
terminated to prevent excessive thrombosis. Thrombin downregulates its own formation 
by the activation of protein C, which gives rise to activated protein C (APC) (Kisiel, 
Canfield et al. 1977; Esmon and Owen 1981; Comp, Jacocks et al. 1982). Numerous anti-
coagulant proteins including specific protease and protease inhibitors such as APC down-
regulate various components of the coagulation response to terminate thrombin formation 
and activity (Rau, Beaulieu et al. 2007). Furthermore, following repair of the damaged 







Figure 1. 1 Protein-enzyme complexes of the coagulation cascade. 
The extrinsic tenase complex, comprised of tissue factor (TF), factor VIIa, and Ca
2+
 
generates factor Xa, which is in complex with platelet factor Va, produces a small 
amount of thrombin. Thrombin activates factor VIIIa together with factor IXa, which is 
also formed by the extrinsic tenase complex, in the intrinsic tenase complex, generates 
additional factor Xa. The convergence of both pathways onto the prothrombinase 
complex, composed of the cofactor, factor Va and the serine protease factor Xa 
assembled on an activated platelet surface in the presence of calcium, allows for the 
explosive production of thrombin. As indicated, thrombin plays multiple roles in the 







1.2 The Prothrombinase Complex: Role of Factor V 
 
 The assembly of protein-enzyme complexes is crucial for hemostasis. The 
prothrombinase complex, in particular, is central to clot formation as it activates 
prothrombin to thrombin, which is involved in numerous procoagulant and anticoagulant 
events. This complex is comprised of the nonenzymatic cofactor, factor Va and the serine 
protease, factor Xa, assembled on an activated platelet membrane surface in the presence 
of Ca
2+ 
(Barton, Jackson et al. 1967; Walsh 1974; Mann, Nesheim et al. 1990) (Figure 
1.2). While all the components of Prothrombinase are necessary for prothrombin 
activation (Nesheim, Taswell et al. 1979), the cofactor factor Va plays a critical role in 
the regulation of blood coagulation via this complex. The prothrombinase complex as a 
whole enhances the catalytic rate of thrombin generation by 300,000-fold as compared to 
factor Xa alone (Nesheim, Taswell et al. 1979). When the cofactor, factor Va, is excluded 
from prothrombinase assembly, the rate of thrombin generation is observed to decrease 
by 10,000-fold.   
 Given the essential role of factor Va in thrombin generation, as expected, a 
deficiency in the procofactor (factor V) results in a bleeding diathesis. Factor V 
deficiency or parahemophilia is a rare autosomal recessive disorder with an incidence rate 
of 1:1,000,000 (Asselta, Tenchini et al. 2006; Segers, Dahlback et al. 2007). 
Parahemophilia is characterized by low or undetectable amounts of facor V that result by 
way of multiple mechanisms, including mutations (missense and nonsense mutations, 








Figure 1. 2 The role of complex formation in thrombin generation. 
The prothombinase complex, comprised of the serine protease factor Xa (FXa), the 
nonenzymatic cofactor, factor Va (FVa), and Ca
2+ 
assembled on the platelet membrane 
surface is crucial in the generation of thrombin. Relative to the activity of factor Xa 
alone, the inclusion of all the Prothrombinase constituents results in a 300,000 fold 
increase in the rate of prothrombin activation. The presence of factor Va in the complex 







MCFD2 genes) of trafficking proteins involved in factor V and factor VIII secretion that 
leads to dual deficiency in factor V and factor VIII, acquired defects, or the development 
of antibodies to factor V (Asselta and Peyvandi 2009; Duckers, Simioni et al. 2009; 
Weiss 2009; Zhang 2009; Franchini and Lippi 2011). 
 
1.3 Factor V: Biochemistry and Physiology 
 
In whole blood, the procofactor, factor V, exists in two pools with approximately 
75-80% circulating in plasma and 20-25% found within platelets (Breederveld, Giddings 
et al. 1975; Osterud, Rapaport et al. 1977; Vicic, Lages et al. 1980; Tracy, Eide et al. 
1982). The platelet-derived factor V pool is stored in platelet α-granules (Chesney, Pifer 
et al. 1981; Wencel-Drake, Dahlback et al. 1986) and is released upon platelet activation. 
Factor V is synthesized by the liver and circulates in plasma as a large molecular weight 
(330 kDa) protein (Rapaport, Ames et al. 1960; Kupfer, Gee et al. 1964). The factor V 
gene (F5), isolated in 1992, is located on human chromosome 1q23 (Jenny, Pittman et al. 
1987; Cripe, Moore et al. 1992), spans 80 kb of DNA, and is composed of 25 exons and 
24 introns. The exons are 72 to 287 base pairs in size, and the introns range from 448 
base pairs to 11.4 kb. Following transcription, the factor V mRNA is 6.9 kb and has a 
6672 bp coding region (Cripe, Moore et al. 1992). Currently, the mechanism underlying 
factor V transcription and translation are unknown. However, it is known that following 
translocation into the endoplasmic reticulum, factor V undergoes several post-
translational modifications, including phosphorylation (Kalafatis, Rand et al. 1993; Rand, 
Kalafatis et al. 1994; Kalafatis 1998; Gould, Silveira et al. 2004), N-linked and O-linked 
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glycosylation (Jenny, Pittman et al. 1987; Fernandez, Hackeng et al. 1997; Silveira, 
Kalafatis et al. 2002), and sulfation (Hortin 1990; Pittman, Tomkinson et al. 1994). 
Additionally, the encoded factor V protein undergoes processing to remove a 28 residue 
signaling peptide resulting in the secretion of a mature human factor V molecule of 2196 
amino acids (Kane and Davie 1986). Factor V circulates in plasma at a concentration of 
21-30 nM (Tracy, Eide et al. 1982) and has a half life of 12-15 hours (Borchgrevink and 
Owren 1961). 
 Early studies in animal models suggested that megakaryocytes synthesize platelet-
derived factor V; and while mouse megakaryocytes do synthesize factor V (Chiu, Schick 
et al. 1985; Gewirtz, Keefer et al. 1986; Yang, Pipe et al. 2003; Rowley, Schwertz et al. 
2012), it is clear that human platelet-derived factor V originates exclusively via 
endocytosis of the plasma-derived procofactor by megakaryocytes (Camire, Pollak et al. 
1998; Bouchard, Williams et al. 2005; Gould, Simioni et al. 2005; Suehiro, Veljkovic et 
al. 2005; Bouchard, Meisler et al. 2008). Megakaryocytes are platelet-progenitor cells 
that reside in the bone marrow. As platelets possess no biosynthetic capability, the 
majority of the proteins that are found in the platelet granules are synthesized by 
megakaryocytes [thrombospondin, plasminogen activator inhibitor-1, and von Willebrand 
factor (Sporn, Chavin et al. 1985; Sitar, Borroni et al. 1986; Konkle, Schick et al. 1993; 
Roussi, Drouet et al. 1995)] or endocytosed from plasma [fibrinogen (Handagama, 
Scarborough et al. 1993), albumin (Handagama, Shuman et al. 1989) , IgG (Handagama, 
Rappolee et al. 1990), and factor V (Bouchard, Williams et al. 2005; Gould, Simioni et 




Figure 1. 3 Megakaryocytes mediate the endocytosis of factor V. 
Megakaryocytes are derived from hematopoietic stem cells and undergo multiple 
differentiation and maturation stages during development in the bone marrow to 
ultimately produce platelets. Panel A) Mature megakaryocyte (Robert, Cortin et al. 
2012). Panel B) Bone marrow-derived CD34+ cells were induced to differentiate into 
megakaryocytes (Bouchard, Williams et al. 2005). Following incubation with 100 nM 
factor V-AlexaFluor488 (green staining) and 100 nM fibrinogen-AlexaFluor633 (red 
staining) (17 hr, 37°C), the cells were visualized by confocal microscopy using a Zeiss 
510 Meta confocal microscope. In the last panel, the individual images were merged 
using the Zeiss 510 software (yellow staining) (Bouchard et al., unpublished 
observations). Original magnification = 630x. In panel A, the scale bar = 2 µm, and in 
Panel B, the scale bars = 10 µm. 
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platelets and megakaryocytes are capable of endocytosis of fibrinogen, IgG and albumin 
(Sporn, Chavin et al. 1985; Sitar, Borroni et al. 1986; Konkle, Schick et al. 1993; Roussi, 
Drouet et al. 1995), factor V is endocytosed by only megakaryocytes (Camire, Pollak et 
al. 1998; Bouchard, Williams et al. 2005). 
Endocytosis of factor V is clathrin-dependent and mediated by two receptors 
including an unidentified specific factor V receptor and low-density lipoprotein (LDL) 
receptor related protein (LRP-1) (Figure 1.4) (Bouchard, Meisler et al. 2008). LRP-1 
belongs to a family of proteins related to the LDL receptor of endocytic receptors (AJ 
1998; Gliemann 1998). LRP-1 is a widely distributed membrane receptor that is known to 
bind multiple, structurally unrelated ligands, targeting most but not all to lysosomes for 
degradation (Hussain, Strickland et al. 1999; Argraves 2001; Herz and Strickland 2001; 
Li, Cam et al. 2001; Bouchard, Meisler et al. 2008).  
 
1.4 Platelet versus Plasma Factor V/Va 
 
Despite their identical biosynthetic origin, plasma- and platelet-derived factor 
V(a) are structurally and functionally distinct.  Studies have shown that the factor V that 
is found in platelets is stored and released as a mixture of intact single chain and partially 
proteolytically-activated factor V (Viskup, Tracy et al. 1987; Monkovic and Tracy 1990). 
This is in sharp contrast to the plasma-derived counterpart, which exists solely in a single 
chain form that does not express cofactor activity. The partially proteolytically active 
form of factor V exhibits significant activity that is ~5-50% the activity of fully 








Figure 1. 4 Hypothetical model of the megakaryocyte cell surface events giving rise 
to platelet-derived factor V. 
Two receptors, including the well-characterized LRP-1 molecule and the as of yet 
unidentified factor V receptor (FV Rc), mediate factor V (FV) endocytosis by 
megakaryocytes. The initial binding of factor V to the FV Rc facilitates subsequent 
binding of factor V to LRP-1 after which factor V is endocytosed in Ca
2+
- and clathrin- 
dependent manners, phenotypically-modified, and trafficked to the α-granules. LRP-1 is 
believed to be trafficked back to the cell surface; however, the fate of the FV Rc is 
unknown.  Additionally, it is unknown whether endocytosis is mediated by LRP-1 in 





(Kane, Lindhout et al. 1980; Vicic, Lages et al. 1980; Kane, Mruk et al. 1982; Viskup, 
Tracy et al. 1987; Monkovic and Tracy 1990), and expresses a minimal increase (~2-3- 
fold) in activity upon activation with thrombin or factor Xa (Monkovic and Tracy 1990). 
In contrast, plasma factor V cofactor activity increases by 400-fold when activated by 
thrombin (Nesheim, Taswell et al. 1979). Furthermore, factor Xa can activate the platelet-
derived factor V more effectively (50-100 times greater) than thrombin (Monkovic and 
Tracy 1990), the known potent activator of plasma factor V.   
Compared to thrombin-activated factor Va, characterization of purified platelet-
derived factor V have indicated that while the heavy chain is intact, the platelet-derived 
factor V light chain has a unique cleavage site at Tyr1543 that also leads to functional 
cofactor activity (Gould, Silveira et al. 2004). With respect to the proteolytic state of the 
partially activated platelet factor V molecule, species consistent with thrombin-activated 
factor V were observed in addition to unidentified peptide fragments that are most likely 
generated by a specific unknown protease(s).  
In addition to the aforementioned differences between platelet and plasma factor 
V, platelet-derived factor V displays other unique physical and functional characteristics. 
A unique O-linked glycoform at Thr402 has been identified on the heavy chain of platelet 
factor V, however it is unknown as to whether this feature exists in all individuals as the 
finding was made using platelet-derived factor V isolated from a platelet pool (Gould, 
Silveira et al. 2004). The Ser692 residue of factor V is known to be phosphorylatable by a 
casein-like kinase enzyme, and casein kinase-2; however, this phosphorylation is only 
observable in plasma factor V and not platelet factor V implying that this form is resistant 
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to phosphorylation by these enzymes (Rand, Kalafatis et al. 1994; Kalafatis 1998; Gould, 
Silveira et al. 2004). The platelet-derived factor Va pool is also partially resistant to 
inactivation by APC (Camire, Kalafatis et al. 1995; Camire, Kalafatis et al. 1998). The 
serine protease, plasmin, which is known to inactivate plasma factor V in the presence of 
a membrane surface (Lee and Mann 1989) leads to increased and sustained activity in 
platelet-derived factor V (Conlon 1997). In the absence of the platelet membrane, no 
increase in activity is observed. Additionally, studies by Wood et al. have indicated that a 
percentage of platelet factor V is non-dissociable and bound to the membrane of the α-
granule via a glycophosphatidylinositol (GPI) anchor (Wood and Fager 2008).  
Several clinical observations support the notion that the platelet-derived factor V 
is more procoagulantly relevant in hemostasis compared to its plasma counterpart 
(Borchgrevink and Owren 1961; Tracy, Giles et al. 1984; Nesheim, Nichols et al. 1986; 
Weiss, Lages et al. 2001; Duckers, Simioni et al. 2010). At sites of vascular damage, the 
concentration of platelet-derived factor Va exceeds its plasma counterpart by 
approximately 100, as platelets contain 20% of the total pool of factor V in whole blood 
and are contained in such a small volume at sites of vascular injury that their 
concentration of factor V surpasses that of plasma (Nesheim, Nichols et al. 1986). The 
clinical importance of platelet-derived factor V is evident in individuals with Quebec 
platelet disorder, which is a hemorrhagic disorder in which platelet factor V levels are 
decreased (Tracy, Giles et al. 1984) due to enhanced proteolysis of factor V by the 
overexpression of urokinase-type plasminogen activator in α-granules (Kahr, Zheng et al. 
2001). Also, in an individual with an inhibitor to plasma-derived factor V, but whose 
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platelet-derived factor V is unaffected, no adverse bleeding was observed and adequate 
hemostasis was supported during surgery (Nesheim, Nichols et al. 1986). Hemostatic 
improvement has also been observed in a factor V deficient patient receiving platelet 
transfusions (Borchgrevink and Owren 1961). The pivotal role of platelet factor V is 
further supported by the severe bleeding problems presented in factor V New York, a 
disorder characterized by defective platelet-derived factor V and normal plasma factor V 
levels (Weiss, Lages et al. 2001).  
Though the significance of platelet factor V in hemostasis has been known for 
decades, its protective role in bleeding pathologies has only recently been closely 
investigated. Individuals with congenital factor V deficiency often present with 
hemorrhagic diatheses of variable severity that correlate poorly with plasma factor V 
levels (Lak, Sharifian et al. 1998). This variation in phenotype may be explained by two 
different studies that have shown patients deficient in plasma factor V with residual 
factor V in their platelets are protected against major bleeding events (Bouchard, 
Brummel Ziedins et al. ; Bouchard, Chapin et al. ; Duckers, Simioni et al. 2010; Castoldi, 
Duckers et al. 2011). Studies by Bouchard et al. showed that transfusions of plasma 
factor V to control gastrointestinal bleeding allowed for hemostatic competence in a 
patient completely devoid of plasma and platelet factor V (Bouchard, Brummel Ziedins et 
al.). Endocytosis of factor V by the patient’s platelets following plasma administration 
was time-dependent. The functional significance of his acquired platelet-derived factor V 
was studied subsequent to plasma administration in a whole blood clotting assay at a 
point in time when no detectable plasma-derived factor V could be observed. When the 
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patient’s platelets were initially maximally activated with PAR1 and 4, clot formation 
and thrombin generation in a tissue factor-based clotting assay were observed. Thus, 
despite a complete absence of detectable plasma factor V, and approximately 7% (0.11 
nM) normal levels of platelet-derived factor V/Va confers hemostatic competence in this 
individual. In a second study (Bouchard, Chapin et al.), no thrombin generation was 
observed in platelet poor plasma obtained from factor V deficient patients; however, 
appreciable amounts of thrombin were generated with the use of their platelet rich 
plasma. Thrombin generation in the platelet rich plasma could be completely inhibited by 
both an anti-factor V antibody and APC. In addition, washed platelets from the factor V 
deficient patients contained measurable levels of the functional factor V antigen 
(Duckers, Simioni et al. 2010; Castoldi, Duckers et al. 2011). Taken together, these 
observations support the notion that platelet-derived factor V is the more hemostatically 
relevant cofactor pool. 
 
1.5 Structure/Function Relationships of Factor V/Va 
 
 Factor V, is a multidomain protein (A1-A2-B-A3-C1-C2) that circulates in 
plasma in a single chain, inactive form.  The activation of factor V can be catalyzed by 
thrombin (Esmon 1979; Nesheim and Mann 1979; Nesheim, Myrmel et al. 1979; 
Dahlback 1980; Monkovic and Tracy 1990), the physiological activator of factor V, and 
other proteases that  include factor Xa (Smith and Hanahan 1976; Foster, Nesheim et al. 
1983), plasmin (Lee and Mann 1989), meizothrombin (Tans, Nicolaes et al. 1994), 
elastase (Camire, Kalafatis et al. 1998), cathepsin G  (Turkington 1993; Allen and Tracy 
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1995), calpain (Rodgers, Cong et al. 1987), and factor XIa (Whelihan, Orfeo et al. 2010), 
which will result in the production of a cofactor with variable amounts of cofactor 
activity. Factor V can also be activated by monocyte-associated (Tracy, Rohrbach et al. 
1983), platelet-associated (Kane and Majerus 1982), and neutrophil-associated proteases 
(Oates and Salem 1987). The degree to which these cellular activators contribute to factor 
V activation in physiological events is unknown. 
 The activation of factor V to Va by thrombin occurs via limited proteolysis at 
Arg709, Arg1018, and Arg1545 (Esmon 1979) (Figure 1.5). Cleavage of factor V by 
thrombin occurs in a stepwise manner with initial cleavage at Arg709 releasing the N-
terminally-derived 105 kDa heavy chain fragment, and a 280 kDa fragment consisting of 
the light chain and the B domain. Cleavage of the 280 kDa fragment at Arg1018 releases 
the 71 kDa B domain, and produces a 220 kDa intermediate. Lastly, cleavage at Arg1545 
of the 220 kDa fragment releases the remainder of the B domain (150 kDa) and the light 
chain (74/71 kDa). The active cofactor, factor Va, is composed of a heavy chain (amino 
acids 1-709) and light chain  (amino acids 1545-2196) component which are non-
covalently linked by a Ca
2+
 ion. The heavy chain (~105 kDa) is comprised of the A1-A2 
domains, while domains A3-C1-C2 form the light chain (~74 kDa). Based on the 
available amino acid sequences of factor V from various species, the A and C domains 
are highly conserved amongst species, including the various species listed in the NCBI 
protein data base (http://www.ncbi.nlm.nih.gov). The factor V A domains share 40% 
homology with the copper transport plasma protein, ceruloplasmin (Ortel, Takahashi et 




     
 
Figure 1. 5 Factor V activation by thrombin. 
Factor V is activated by thrombin via three cleavages. An initial cleavage at Arg709, will 
produce a heavy chain fragment of 105 kDa, and another fragment of 280 kDa. Another 
cleavage at Arg1018 will remove the 71 kDa B domain fragment leaving a large 220 kDa 
fragment. Finally, cleavage at Arg1545 will produce another B domain fragment (150 
kDa) and a light chain fragment of 74 kDa. The three cleavages, collectively, result in the 
release of the B domain and yield the activated form of the procofactor, factor Va 
comprised of heavy (105 kDa) and light chain (74 kDa) components that are 









protein family from the slime mold Dictyostelium discoideum (Jenny, Pittman et al. 
1987). The coagulation protein, factor VIII, that has a domain arrangement identical to 
that of factor V, shares 40% sequence identity in both the A and C domains, while the B 
domains in both proteins are only 14% homologous (Kane and Davie 1988). Unlike the A 
and C domains, the B domain is poorly conserved amongst the studied factor V species 
(Nicolaes and Dahlback 2002; Mann and Kalafatis 2003), and possesses unique tandem 
repeats, the function of which remains to be studied. Release of the B domain appears to 
result in the removal of the conformational constraints that inhibit factor V activity. 
Insight into this observation was made using a partially B-domainless mutant form of 
factor V lacking residues 811-1491 (FV des811-1491, FV-DT), that was observed to have 
partial, constitutive activity compared to thrombin-activated factor V (Kane, Devore-
Carter et al. 1990; Keller, Ortel et al. 1995). Further studies have identified a region 
within the B domain that is important for factor V activation. The region is highly basic, 
and deletion of this region yields a factor V derivative with cofactor properties in the 
absence of proteolysis with thrombin, suggesting that the full length B domain is not 
responsible for the maintenance of an inactive state, but rather the inhibition of activity is 
brought upon by specific B domain sequences, some of which remain unidentified (Zhu, 
Toso et al. 2007) .   
 
1.5.1 Factor Va Interaction with Membranes   
 
 Several protein-protein interactions and protein-membrane interactions are 
essential for factor Va function. The binding of factor Va to membrane surfaces is crucial 
for its function given the membrane dependence of the prothrombinase complex, the 
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binding of factor Va to Xa, and the inactivation of factor Va by APC. Studies with 
synthetic phospholipid vesicles (Kim, Quinn-Allen et al. 2000; Nicolaes, Villoutreix et al. 
2000) and activated platelets (Tracy and Mann 1983) have provided substantial 
information concerning factor Va membrane interactions, and have collectively suggested 
a role for the factor V light chain in phospholipid binding. In 1983, Tracy et al. showed 
that the factor V light chain mediates prothrombinase complex assembly on activated 
platelets (Tracy and Mann 1983). In their studies, the 74 kDa component of factor V 
dissociated from the heavy chain component with the use of EDTA was observed to 
associate with the platelet surface.  
 The binding of factor Va to synthetic phospholipid vesicles has also been shown 
to occur via the light chain of factor V. Phospholipids composed of 25% 
phosphotidylserine (PS) and 75% phosphotidylcholine (PC) allow for favorable binding 
of factor Va with a dissociation constant of 10
-9
 M (Izumi, Kim et al. 2001). Unlike 
membrane binding of the vitamin K-dependent coagulation proteins, factor Va binding to 
phospholipids is not calcium-dependent (Higgins and Mann 1983; Krishnaswamy and 
Mann 1988). Studies performed using lipophilic probes, mutagenesis studies, as well as 
X-ray crystallography have shown that factor Va membrane binding sites are localized 
within the A3, C1 and C2 domains of the light chain (Kalafatis, Rand et al. 1994; Kim, 
Quinn-Allen et al. 2000; Adams, Hockin et al. 2004; Peng, Quinn-Allen et al. 2005).   
 The phospholipid binding site in the A3 domain was identified, and characterized 
by Kalafatis et al. by proteolysis of a phospholipid-bound isolated form of the light chain 
(Kalafatis, Jenny et al. 1990). The regions protected from proteolytic cleavage covered 
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the A3 domain, and were observed to interact with phospholipid vesicles directly. 
Collectively, their findings indicated that a 99-amino acid segment, featuring residues 
1667-1765 in human factor V, localized within the central part of the A3 domain is 
involved in membrane binding. Although the sites within the region that directly 
interacted with the membrane surfaces were undefined, hydropathy plots suggested that 
two hydrophobic regions, 1716-1727 and 1741-1748, are involved in the interaction of 
the light chain with phospholipid vesicles.  
 Studies on the contribution of the factor V C1 domain to membrane binding were 
initially conducted by Saleh et al. using a molecular model of the C1 domain that was 
constructed based on the factor V C2 domain structure. Two residues of the C1 domain 
(Tyr1956/Leu1957) located at the predicated apex of a β-hairpin loop analogous to the 
previously identified Trp2063/Trp2064 membrane binding sites of the C2 domain were 
mutated by alanine-scanning mutagenesis, and screened for phospholipid binding and 
prothrombin activity. The mutant Y1956A/L1957A interacted weakly with phospholipid 
vesicles using fluorescent resonance energy transfer (FRET), and its binding affinity was 
observed to decrease by 12-fold in comparison to the native protein. In addition, the 
Y1956A/L1957A mutant was found to markedly decrease prothrombinase activity on 
phospholipid vesicles. A second mutant (R2023A/R2027A) was also observed to have 
decreased binding to phospholipid vesicles and was demonstrated to impair procoagulant 
activity. Ultimately, the study showed that two pairs of amino acids-Y1956/L1957 and 
R2023A/R2027A within the C1 domain contribute to the binding of factor V to 
membranes. A later study by Peng et al. showed that the mutation of the proposed C1 
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membrane binding sites (Y1956/L1957) in combination with mutations in the previously 
identified C2 membrane binding sites (W2063/W2064) results in a four-fold decrease in 
thrombin generation (Peng, Quinn-Allen et al. 2005).  
 The C2 domain of factor V, which lies in tandem with the C1 domain, has also 
been shown to contain determinants of membrane binding (Ortel, Devore-Carter et al. 
1992; Gilbert, Novakovic et al. 2012). Studies with anti-factor V antibodies directed 
toward the C2 domain have been shown to alter both function and membrane binding 
(Ortel, Moore et al. 1998)  In addition, the deletion of the C2 domain has been observed 
to result in the loss of the PS binding potential of factor Va (Ortel, Devore-Carter et al. 
1992). The crystal structure of the factor V C2 domain revealed hydrophobic residues 
(Trp2063 and Trp2064) at the apex of three β-hairpin loops of a beta barrel motif 
corresponding to the C2 domain that were suggested to line a groove also containing 
polar residues, that can be inserted into membranes (Macedo-Ribeiro, Bode et al. 1999). 
The factor V model based on the bovine factor Vai crystal structure (Adams, Hockin et al. 
2004) with a modeled A2 domain from ceruloplasmin (Orban, Kalafatis et al. 2005) 
confirmed these data and identified a similar membrane binding site in the C1 domain. 
The bovine factor Vai structure also predicted that the membrane binding site within the 
A3 domain is positioned away from the C domains.  
  Other studies have demonstrated a role for N-linked glycosylation of the light 
chain in modulation of factor Va membrane binding. Asn2181 in the C2 domain, which is 
within close proximity of the membrane binding region, is differentially glycosylated. By 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), this differential 
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glycosylation gives rise to two factor Va light chain isoforms, factor Va1 (71 kDa) and 
factor Va2 (74 kDa) (Kim, Ortel et al. 1999; Nicolaes, Villoutreix et al. 1999). Factor Va1, 
the glycosylated form, binds phospholipids with a much lower affinity than factor Va2, 
and therefore has lower cofactor activity in prothrombinase (Rosing, Bakker et al. 1993; 
Kim, Ortel et al. 1999; Nicolaes, Villoutreix et al. 1999). Collectively, these studies have 
provided both mechanistic and structural evidence for a role of the factor V light chain in 
membrane binding. 
 
1.5.2  Interaction of Factor Va with Factor Xa 
 
Aside from enhancing the catalysis of the factor Xa-mediated cleavage of 
prothrombin (Krishnaswamy 1990), factor Va serves as part of the receptor for factor Xa 
in the prothrombinase complex, forming a high affinity complex with the protein. Upon 
binding to the platelet membrane surface, both the heavy and light chains of factor Va 
contribute to binding factor Xa (Kalafatis and Beck 2002). Several studies have 
demonstrated the localization of factor Xa binding sites in factor Va. Based on peptide 
inhibition studies, a number of factor Xa binding sites have been identified in the heavy 
chain of factor V, including residues 311-325, 323-331, and 493-506 (Heeb, Kojima et al. 
1996; Kojima, Heeb et al. 1998; Kalafatis and Beck 2002). In addition, when site-
directed mutagenesis was used to create recombinant factor V constructs, residues 467, 
511, and 653 in the heavy chain were identified (Steen, Villoutreix et al. 2002).  It has 
also been observed that in the absence of a specific heavy chain region (Asp683-Arg709), 
factor Xa has reduced cofactor activity and the binding between factor Xa and 
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prothombin becomes impaired also suggesting that part of the heavy chain of factor V is 
important for optimal interaction between both proteins (Bakker, Tans et al. 1994). This 
binding interaction between both factor Va and Xa requires the presence of a membrane 
surface (Kd ~3 nM), without which the binding interactions decrease by three orders of 
magnitude and are tremendously weaker (Kd ~ 1 µM) (Bloom, Nesheim et al. 1979; 
Tracy, Peterson et al. 1979; Pusey, Mayer et al. 1982; Higgins and Mann 1983; 
Monkovic and Tracy 1990). To date, only a single factor Xa binding site has been 
identified in the light chain of factor V at His 1683 (Steen, Villoutreix et al. 2002). 
Factor Xa also plays a role in cleaving factor V and similar to thrombin, can 
cleave factor V at Arg 709, 1018, and 1545 to form an active cofactor molecule 
(Monkovic and Tracy 1990; Keller, Ortel et al. 1995; Thorelli, Kaufman et al. 1997). 
However, this cleavage occurs at a rate that is two orders of magnitude less than factor V 
cleavage with thrombin because the enzyme-substrate ratio (1:10) required for efficient 
catalysis is not met. At high factor Xa concentrations, both factor V and factor Va, can be 
cleaved at Arg1765 within the A3 domain of the light chain (Tracy, Nesheim et al. 1983; 
Odegaard and Mann 1987; Thorelli, Kaufman et al. 1997) (Figure 1.6). This cleavage 
gives rise to an N-terminally derived 30 kDa fragment and a C-terminally derived 48/46 
kDa fragment in both human (Thorelli, Kaufman et al. 1997) and bovine forms of factor 









Figure 1. 6 Cleavage of factor Va by factor Xa. 
Factor Xa cleaves the light chain of human factor Va at Arg1765, generating an N-
terminally derived 30 kDa fragment (A3), and a 48/46 kDa fragment (A3, C1 and C2), 










1.6 The Factor V Region Mediating its Endocytosis by Megakaryocytes 
 
 Despite knowing a great deal regarding factor Va’s structural features important 
for its function in Prothombinase, little is known about the factor V domains important 
for its interactions with the megakaryocyte two receptor system and its endocytosis. Of  
the two megakaryocyte receptors known to participate in factor V endocytosis, only LRP-
1 is well-characterized. LRP-1 is composed of an 85 kDa membrane spanning C-terminal 
region that is noncovalently associated with a 515 kDa N-terminal extracellular region 
(Herz, Kowal et al. 1990). LRP-1 binds to its ligands via its extracellular domain, whilst 
its cytoplamic domain binds to adaptor proteins that serve as a link between LRP-1 and 
other membrane proteins (Gotthardt, Trommsdorff et al. 2000). Within the extracellular 
domain are four ligand binding domains termed clusters I, II, II, and IV (Willnow, Orth et 
al. 1994). The LRP-1 ligand binding domains are composed of arrays of cysteine-rich, 
calcium-binding regions termed complement-type repeats. Studies have also shown that 
lysine side chains are implicated in ligand binding to LRP-1 (Lenting, Neels et al. 1999; 
Bovenschen, Boertjes et al. 2003). The binding of all ligands to LRP-1 is inhibited by 
receptor associated protein (RAP), an endoplasmic reticulum chaperone protein that 
prevents improper folding of LRP-1 prior to transport to the cell surface. One LRP-1 
ligand, factor VIII, which displays an overall amino acid identity of 30% to factor V, 
possesses two high-affinity LRP-1 binding domains within its A2 domain (R484-F509) 
and A3 domain (E1811-K1818) that include the lysine residues at positions 493, 496, and 
499, and positions 1813 and 1818 respectively (Saenko, Yakhyaev et al. 1999; Sarafanov, 
Ananyeva et al. 2001; Sarafanov, Makogonenko et al. 2006; Sarafanov, Makogonenko et 
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al. 2007). More recently, the C1 domain residues Lys2092 and Phe2093 of factor VIII have 
been found to be important for endocytic uptake by LRP1 (Meems, van den Biggelaar et al. 
2011). As little information pertaining to factor V’s LRP-1 binding site could be 
ascertained based on its known homology to other ligands, the primary amino acid 
sequences in the A and C domains of factor VIII and factor V were compared since both 
share 40% identity in these regions. Of all the factor VIII regions/sites involved in LRP-1 
binding, only the region within the A3 domain (E1811-K1818) was found to have some of 
the same residues as the corresponding region in the A3 domain of factor V. However, a 
peptide mimicking this region was observed to have no effect on endocytosis of factor V by 
megakaryocytes (data not shown).  
 Experiments were subsequently performed using various factor V molecules and 
monoclonal antibodies to identify regions of factor V important for its endocytosis by 
megakaryocytes (Bouchard et al., unpublished observation). Initially, the ability of 
various human and bovine factor V and Va molecules, and isolated factor V domains to 
inhibit endocytosis of 
125
I-labeled factor V by megakaryocytes was studied using the 
megakaryocyte-like CMK cell line. Both thrombin-activated human and bovine factor Va 
and the intact procofactors, which display high sequence identity within their heavy 
(84%) and light (86%) chains with a less identical B-domain (59%) (Guinto and Esmon 
1984) inhibited 
125
I-factor V endocytosis by megakaryocytes when present at a 50-fold 
molar excess (Table 1). Similarly, a 50-fold molar excess of isolated human factor V light 
chain inhibited 
125
I-factor V endocytosis by ~85%. In contrast, human factor V heavy 
chain had little effect on 
125
I-factor V endocytosis (~20% inhibition). B-domainless factor 
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V also substantially inhibited 
125
I-factor endocytosis. These observations suggest that 
factor V binding and/or endocytosis is mediated primarily by the light chain, and confirm 
that the B-domain is not involved. Similar experiments were performed using 
recombinant factor VIII. Consistent with a role for LRP-1 in factor V endocytosis, factor 
VIII inhibited 
125
I-factor V uptake to the same degree as unlabeled factor V (~100%) 
when both were present at a 25-fold molar excess. However, at its plasma concentration 
(1 nM) (Hoyer 1981), inhibition was not observed (data not shown). 
  In subsequent experiments, the ability of various anti-factor V antibodies to 
inhibit 
125
I-labeled factor V endocytosis was determined. Consistent with the results of 
the studies performed with various factor V molecules (see Table 1), anti-factor V light 
chain antibodies, E9, #2, and #5, inhibited factor V endocytosis by megakaryocytes by 
greater than 80% (Figure 1.7). One of these antibodies, E9, inhibited 
125
I-factor V 
endocytosis to the same extent as unlabeled factor V. Another anti-factor V light chain 
antibody (#9), as well as an anti-factor V heavy chain antibody (#17) had little or no 
effect on factor V endocytosis (≤ 20% inhibition). This latter observation is consistent 
with the inability of isolated factor V heavy chain to inhibit 
125
I-factor V endocytosis.  
 
1.7 Clinical Relevance of Characterizing the Megakaryocyte Receptor System 
Mediating Factor V Endocytosis 
  
 As the platelet-derived pool of factor V represents the more physiologically 
relevant cofactor, understanding the cellular events mediating factor V endocytosis by 
megakaryocytes would advance studies aimed at developing forms of therapy that 






Table 1. Inhibition of factor V endocytosis by various human and bovine factor V 




Cells in serum-free medium were incubated in the presence of 50-fold molar excesses of 
intact human or bovine factor V and thrombin-activated factor Va; isolated human factor 
V heavy or light chain; or a recombinant, partially B-domainless human factor V 
construct. Molar excesses (25-fold) of human factor VIII and human factor V were also 
utilized. Following a 1 hr incubation (37°C), 
125
I labeled factor V (10 nM) was added (1 
hr, 37°C). To remove excess, as well as bound 
125
I-factor V, cells were washed 
extensively by centrifugation (250 x g, 7 min) followed by resuspension in 20 mM 
Hepes, 0.15 M NaCl, pH 7.4. The radioactivity associated with the dry cell pellet was 







Figure 1. 7 Inhibition of factor V endocytosis by megakaryocytes with various anti-
factor V antibodies. 
125
I-factor V (5 nM) was preincubated (1 hr, 37°C) with anti-factor V light chain (LC) 
(E9, #2, #5 and #9) or heavy chain (HC) (#17) antibodies (1.0 µM) prior to the addition 
of CMK cells. Excess and cell surface-associated 
125
I-factor V were removed, and the 
radioactivity associated with the dry cell pellets assessed as described in Table 1. The 
data are expressed as the percent cpm associated with the cells in the presence of 
antibody as compared to the cpm associated with the cells in the absence of antibody. The 
effect of incubation with a 50-fold molar excess of unlabeled, human factor V (FV) was 






the prevention of cardiovascular events. Given the importance of platelet factor V in 
blood coagulation, anticoagulant drugs could be developed that target the mechanism by 
which plasma factor V is internalized by megakaryocytes. Anticoagulant drugs function 
by way of multiple mechanisms, that include inhibition of enzymes involved in the 
addition of carboxyglutamic acid to the vitamin K-dependent coagulation proteins 
(Warfarin), targeting serine protease that are involved in blood coagulation for activation 
(Heparin), and blocking receptors that are crucial for platelet adhesion, aggregation, and 
fibrinogen binding (Clopidogrel). In a similar manner, drugs that target the 
megakaryocytes receptors involved in endocytosing factor V could prevent factor V 
internalization, and thus the formation of the more procoagulant form of factor V, 
platelet-factor V. It would be expected that the megakaryocytes would continue to 
fragments into platelets therefore intact platelets would still be preserved in whole blood; 
however, the absence of platelet factor V in the platelets would significantly reduce the 
efficiency of blood coagulation as factor V enhances the catalytic rate of prothrombin 
activation in the prothrombinase complex, and the ratio of platelet to plasma factor V at 
the site of injury far exceeds that of plasma to platelet factor V. 
Additionally, the megakaryocyte endocytic receptor system could be exploited to 
develop ways to introduce factor VIII into the platelets of individuals with hemophilia A 
due the structural similarities between factor VIII and V. In individuals with hemophilia 
A, which is characterized by a deficiency in factor VIII, who are on replacement factor 
VIII therapy, the production of neutralizing factor VIII antibodies presents complications. 
Therefore, extensive work is being done that includes studies ranging from gene therapy 
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to drug development against potential inhibitors of factor VIII in an attempt to regulate 
factor VIII levels in these patients. Since factor VIII is homologous to factor V, and 
furthermore serves as an LRP-1 ligand, the identification of the receptor binding regions 
in the light chain of factor V could allow for the manipulation of factor VIII such that it 
can be endocytosed by megakaryocytes, and ultimately stored in platelets. This would 
lead to the maintenance of intact factor VIII in platelets, and contribute to balance in 
hemostasis in individuals with hemophilia A.  
   
Summary 
 Studies aimed at understanding the mechanism by which factor V is internalized 
by megakaryocytes are important given the significance of platelet factor V in 
maintaining normal hemostasis, and the fact that this cellular process could be 
manipulated to develop potential therapies aimed at maintaining normal hemostasis. 
Presently, the endocytic mechanism is not fully characterized, and key questions 
including the identity of the regions of factor V that are involved in interacting with the 
megakaryocyte receptors remain to be addressed. The goal of the studies detailed in this 
thesis was to epitope map anti-factor V antibodies found to inhibit internalization of 
factor V by megakaryocytes. In Chapter 2, conventional approaches for epitope mapping 
antibodies will be described. Chapter 3 will define the approaches utilized in the current 
study, as well as the results of these experiments. Finally, future approaches to 















































 Epitope mapping is a key step in antibody characterization, particularly in 
instances where that antibody serves as a research tool or is used in therapeutic strategies. 
It can provide substantial information regarding protein and ligand recognition for 
understanding structure-function relationships important for biological processes. The 
identification of antigen epitopes can aid in the design of vaccines for the treatment of 
viral diseases. Antibodies can shed light on causes of disease found to have a neutralizing 
potency, as certain diseases are a result of antibodies elicited by microorganisms and 
unrelated proteins. Functionally important residues on proteins can also be identified 
through epitope mapping of antibodies that are known to effect protein function. 
Antibodies that have defined binding sites can also serve in determining the topology of 
transmembrane proteins and protein orientation with respect to intracellular structures. 
Furthermore, antibodies are important for the medical diagnosis of certain diseases, 
including HIV and Hashimoto’s disease (Zaletel 2007; Kalus, Wilkemeyer et al. 2011). 
The focus of this thesis is epitope mapping studies of monoclonal antibodies to define a 
receptor binding site(s) within the coagulation protein, factor V.  
 
2.1 Molecular Structure of Antibodies 
 
 Antibodies (150 kDa) are comprised of four polypeptide chains, two heavy (H) 
and two light (L) chains of 50 kDa and 25 kDa, respectively (Figure 2. 1a). The structure 
of the heavy chain determines which immunoglobulin (IgG) class an antibody will fall 
into- IgE, IgM, IgA, IgD, or IgG-with the later isoform being the most prevalent in 








Figure 2. 1 Structural characteristics of antibodies 
 
a) Antibodies are composed of four polypeptide chains (two identical heavy or H chains 
and two identical light or L chains). The two heavy chains are covalently linked to the 
two light chains through disulfide bridges. Each chain contains N-terminal variable (V) 
and C-terminal constant (C) regions. Each H chain is divided into a specific number of 
immunoglobulin domains depending on the antibody isotype. In the case of IgG, each 
heavy chain contains a VH, CH1, CH2, and CH3 domains, while each L chain contains a 
single variable and constant domain (VL and CL). The VL and CL domains are disulfide 
linked to the VH and CH1 domains forming the Fab domain of an antibody that is linked to 
the Fc domain through a hinge region that is formed by the noncovalent association of the 
remaining constant domain of the heavy chain (CH2 and CH3). (b) The building blocks of 
antibodies are the immunoglobulin domains, comprised of a pair of antiparallel β–sheets 
held in place by three loops (CDR1, CDR2, and CDR3) on each extremity that adopt a 
unique conformation termed the immunoglobulin fold. (c) Each heavy and light chain 
variable region possesses three CDR regions, namely VHCDR1, VHCDR2,VHCDR3, and 
VLCDR1, VLCDR2, VLCDR3 that form the antigen binding site of an antibody. (d) The 
crystal structure of hen egg lysozyme (HEL) antibody-antigen complex. Lysozyme 
(yellow) interacts with residues (red) at the interface of the antibody and antigen 
complex. This figure was used with permission from Springer Science + Business Media, 
























The IgG light and heavy chains contain repeating, independent immunoglobulin domains 
of approximately 110 amino acid residues in length that fall into one of two categories, 
variable (V) or constant (C). Each heavy chain is divided into an N-terminal variable 
domain (VH) followed by three constant domains (CH1, CH2, and CH3). Conversely, each 
light chain is composed of a single variable (VL) and constant domain (CL) that are 
covalently linked with the VH and CH1 domains through disulfide bridges. Both the heavy 
chains are also linked via disulfide linkages. 
 In 1959, Rodney Porter showed using papain that IgG can be cleaved into three 
fragments: two antigen binding fragments termed Fab (F corresponds to fragment, and ab 
to antigen binding) (Porter 1973), which consist of the N-terminal half of the heavy chain 
(VH and CH1), and the entire light chain (VL and CL), and the Fc fragment (fragment 
crystallizable) that contains both C-terminal heavy chain halves (CH2 and CH3). The Fab 
fragments are linked via a flexible hinge region to the Fc fragment. The N-terminal 
variable regions of the Fab fragments mediate antigen binding, and the central paradigm 
is that the unique structural arrangement of the immunoglobulin domain of the variable 
region accounts for the high degree of specificity exhibited by antibodies.  
 The immunoglobulin domains, which serve as antibody building blocks, each 
have a common structure (Figure 2. 1b). The structure of an immunoglobulin domain 
consists of a pair of beta sheets organized in antiparallel fashion that form a central 
hydrophobic core with three loops that lie at one end of the structure forming a binding 
surface. The loop contains a variety of amino acids that are responsible for the generation 
of diverse antibody structures with distinct interaction surfaces that are highly specific. 
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The three loops are referred to as the complementarity determining regions (CDRs) or the 
hypervariable regions. From the N-terminal end of either the VL or VH, the regions are 
called CDR1, CDR2, and CDR3, and of all the CDRs, CDR3 is the most variable. The 
variable regions (VH and VC) are each composed of two immunoglobulin domains and 
therefore have a total of six loops or CDRs (VHCDR1, VHCDR2, VHCDR3 and VLCDR1, 
VLCDR2, VLCDR3) that come together to form an antigen binding site or paratope 
(Figure 2. 1c). IgGs contain two antigen binding sites and therefore can bind two 
epitopes. It is the combinatorial association between the CDRs on the VL and VH and the 
three dimensional structure formed by these regions that allows for specific antibody 
recognition and antigen binding. The first direct evidence of the CDRs forming the 
antigen binding site and being important for specificity came from structural analysis of 
antibodies with hapten ligands, including phosphorylcholine and vitamin K1 (Haselkorn, 
Friedman et al. 1974; Padlan, Davies et al. 1976). Figure 2. 1d highlights the involvement 
of CDR’s at the interface of lysoyme in complex with the Fab fragment of a lysozyme 
antibody (Amit, Mariuzza et al. 1986).  
 The same principles involved in the binding of substrates to enzymes also apply 
to the binding of antigens to antibodies. Antibody-antigen binding involves noncovalent 
interactions, including hydrogen bonds, van der Waals interactions, electrostatic 
interactions, and hydrophobic interactions that allow for strong, specific, and reversible 
binding. These interactions together with overall surface complementarity (Rini, Schulze-
Gahmen et al. 1992) determine antibody affinity, and most antibodies have affinities for 




M (Kranz, Herron et al. 1981; 
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Kranz, Herron et al. 1982; Foote and Eisen 1995) regardless of the nature of the 
antibody’s epitope. Aside from proteins, antigens that bind antibodies can also include 
polysaccharides, carbohydrates, nucleic acids and lipids, however proteins are the only 
antibody binding partners that can evoke an immune response. Studies have shown that 
the topology of the antigen binding site of an antibody can vary significantly depending 
on antigen size. Small antigens typically bind in the cleft of the antigen binding site, 
whilst macromolecules interface with the extended surfaces in the binding site of the 
antibody (Jones and Thornton 1996; MacCallum, Martin et al. 1996). Although 
antibodies are highly specific towards antigens, it is not unusual for them to cross-react 
with molecules that are structurally similar, but unrelated (Berzofsky and Schechter 
1981). An example of cross-reactivity is that of a mouse monoclonal IgE antibody against 
the hapten 2, 4–dinitrophenol that binds with high affinity (Kd-20 nM) (Eshhar, Ofarim et 
al. 1980), which has also been observed to bind other small molecules with varying 
affinity, including a structurally unrelated protein, Trx-shear 3 (Varga, Kalchschmid et al. 
1991). 
 The epitopes on antigens, also known as the antigenic determinant, that antibodies 
recognize and bind to are comprised of a small number of amino acids. The antigenic 
determinant as a whole, however, is made up of a greater number of amino acid residues 
besides those involved in direct binding. Epitopes fall under one of two categories: linear 
(continuous) or conformational (discontinuous) epitopes (Sela 1969). Linear epitopes are 
composed of adjacent amino acid residues in a polypeptide chain that are presented to the 
antibody regardless of whether or not the protein is in its native state. Therefore, even 
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with the application of proteolytic enzymes to produce protein fragments, a linear epitope 
is highly likely to remain intact and detectable by an antibody though the interactions 
between the antibody and the linear antigen fragment tend to be weaker as it does not 
retain the conformation present in the folded protein. In contrast, discontinuous epitopes 
are highly dependent on protein conformation and are formed by the spatial organization 
of amino acids formed as a result of protein folding. When an antibody that recognizes 
conformational epitopes is presented with its antigen partner in an unfolded state, it is 
highly unlikely that the epitope will be detected. There are exceptions however, as ~10% 
of antibodies that target conformational epitopes are able to bind fragments from a target 
antigen because linear epitopes can in fact comprise a large portion of a discontinuous 
epitope (Barlow, Edwards et al. 1986). The binding affinity of antibodies to such epitope 
fragments is typically low considering that such epitope fragments are part of a more 
complex whole.  
 The discovery of monoclonal and polyclonal antibodies has made it possible to 
design antibodies against specific antigens, which can be used as specific tools in 
biomedical studies. Monoclonal antibodies, which are produced from a single clone of B 
cells, are highly specific and detect a single epitope, whereas polyconal antibodies can 
bind to a variety of epitopes. Although, both antibody types are extensively used for 
research purposes, epitope mapping studies are primarily performed using monoclonals 
due to their high degree of specificity. The conventional methods that are used in epitope 




2.2 Epitope Mapping Methods 
 
 There are a number of different methods described in several reviews that can be 
utilized to epitope map antibodies (Johne, Gadnell et al. 1993; Kustanovich and Zvi 
1996; Megy, Bertho et al. 2006). The approach one decides to employ is largely 
dependent on the nature of the antibody epitope, therefore it is essential to distinguish 
between linear and conformational epitopes as an initial step. One of the simplest ways to 
determine whether an antibody recognizes a linear epitope versus a conformational 
epitope is by Western blotting. If the antibody is unable to bind after the protein has been 
denatured using SDS, and analyzed under both reducing and nonreducing conditions, it is 
highly likely that the antibody epitope is conformational-dependent. Furthermore, under 
both reducing and nonreducing conditions, it can be determined if the epitope is 
dependent on a formed disulfide bond. Epitopes that are defined from a structural 
standpoint typically feature the contact amino acid residues at the interface of the 
antigen-antibody complex, and are therefore generally comprised of a large number of 
residues. In contrast, epitopes that are identified using a functional-based method are 
comparatively smaller and primarily consist of residues that play a direct role in antibody 
binding. Neither approach is selective as both can be utilized in epitope mapping 
antibodies with epitopes of a linear or conformational nature, however, not every 
structural- or functional- based method can be used to identify both epitope types. 
Finally, it is important to note that linear epitopes are easier to map relative to 
conformational epitopes given that the complete analysis of epitopes of this nature must 
be done within the framework of the native antigen structure.  
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2.3 Structural Approaches 
 
2.3.1 X-ray Cystallography 
 
 Crystallographic analysis is a structural approach to epitope mapping that allows 
for direct visualization of the amino acids involved in interacting with an antibody. While 
these types of data would be unequivocal, this method is not the most practical and very 
few epitopes have been mapped this way. Antibody-antigen complexes typically reveal 
on average between 15-20 amino acid contact residues (Amit, Mariuzza et al. 1986), 
whereas the conventional functional epitope mapping approaches generally identify 
fewer important contact residues. The crystal structure of lysozyme in complex with a 
Fab fragment from a lysozyme antibody was generated in 1986 (Amit, Mariuzza et al. 
1986). The interface between the antibody and antigen was observed to be tightly packed 
with 16 lysozyme residues and 17 antibody residues that were closely associated (see 
Figure 2. 1d). Van der Waals and hydrogen bonding interactions were primarily involved 
in the interaction, and the CDR3 region in the VHeavy chain region was found to contribute 
significantly to the formation of the complementary antibody-antigen complex, which 
further illustrates the importance of CDRs in generating distinct functional antibody 
binding sites. To date, there exists a limited number of available antigen-antibody 
structures.  
2.3.2 Nuclear Magnetic Resonance 
 
 Nuclear magnetic resonance (NMR) is another structural approach that is 
complementary to X-ray crystallography (Zvi, Kustanovich et al. 1995; Megy, Bertho et 
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al. 2006). Unlike crystallography, NMR is performed in solution so crystal generation is 
not an issue, however antigen size is a limiting factor and the method is therefore better 
suited to peptide antigens and unsuitable for the study of complex epitopes. This method 
is primarily used to characterize the interaction between the antigen-antibody 
immunocomplex, and typically a priori information regarding the reactivity of the antigen 
or peptide with the antibody is required. To define the amino acids of the antigen that are 
in contact with the antibody, small peptides against the antibody of interest are 






N), and used to assemble an 
immunocomplex that is then analyzed by NMR. The epitope of anti-gp120, a human 
immunodeficiency virus (HIV) antibody, was mapped by NMR using a 24 amino acid 
peptide (RP135), that corresponded to an antigenic determinant of the virus glycoprotein 
gp120 (Zvi, Kustanovich et al. 1995). The complex of RP135 with the anti-gp120HIV 
neutralizing antibody, which cross-reacts with the peptide, featured 14 contact residues as 
part of the antigenic determinant recognized by the antibody that was further confirmed 
by competition binding with truncated RP135 peptides. 
 
2.3.3 Computational Methods    
 
 Another structure-based epitope mapping approach is the use of computational 
epitope prediction tools that are based on the knowledge of a protein’s three-dimensional 
structure and/or sequence. These bioinformatics tools typically target structural properties 
and protein characteristics that could be used to identify potential epitope regions within 
proteins. The first attempts at epitope prediction based on protein structure began in 1984 
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when temperature factors, a crystallographic parameter, were found to correlate with 
epitopes in lysozyme, the tobacco mosaic virus, and myoglobin (Westhof, Altschuh et al. 
1984). Thornton and colleagues also found that areas of high protrusion indexes in 3D 
structures corresponded to protein epitopes in myohaemerythrin and lysozyme (Thornton, 
Edwards et al. 1986). Additionally, a relationship between epitopes and solvent 
accessibility as well as flexibility of the antigen determining region was established 
(Novotny, Handschumacher et al. 1986). These findings gave rise to the web-based tools 
that allow for the prediction and visualization of epitopes in the primary and 3D structure 
of proteins.  
 An example of an epitope prediction tool that can be described as a structure-
based function recognition method is one originally designed by Delisi et al. that utilizes 
all-atom molecular dynamic simulation in monitoring protein motions on a timescale that 
reveals interactions and conformations that could be important for function and 
recognition (Ma, Wolfson et al. 2001; Glazer, Radmer et al. 2009; Kamberaj and van der 
Vaart 2009). This de novo prediction method has been utilized in predicting epitopes in a 
number of drug-based studies (Lerner, Bowman et al. 2007; Glazer, Radmer et al. 2009). 
Using molecular dynamics, the epitope of H5N1 hemagglutinin 1046T was predicted 
based on molecular dynamics simulations on monoclonal antibody variable fragment 
8H5Fv (Mulyanto and Saleh 2011). Another example of an epitope prediction tool is one 
that combines protein dynamics and energetics to determine low intensity, energetic 
interaction networks in the protein structure (Scarabelli, Morra et al. 2010). The idea is 
that epitopes may correspond to regions that interact with other parts of the protein via 
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low intensity energy interactions, which triggers conformational changes within the 
protein.  
 This method requires the use of protein antigens for which crystal structures are 
available either in isolation or in complex with an antibody so that the validity of the 
epitope prediction can be verified using the corresponding structure of the antibody-
antigen complex. Additionally, these in silico approaches are typically combined with in 
vitro approaches to verify the predicted epitopes. A number of other prediction methods 
that utilize other epitope features in prediction including solvent accessibility, and spatial 
distribution also exist. As the available X-ray crystallographic structures of antigen-
antibody complexes in the protein data bank (PDB) continue to grow, it is anticipated that 
there would be an increased utilization of 3D structure-based prediction methods. 
 
 
2.4 Functional Approaches 
 
 The functional epitope mapping approaches can be divided into four major 
categories 1) competition methods 2) protein/antigen modification 3) fragmentation 
methods and 4) use of synthetic peptides. These methods primarily entail the introduction 
of a variable into the immunocomplex, which is then followed by testing for the antigen 
function. 




 The basic principle behind this method is to determine whether two antibodies 
would bind an antigen at the same time, which would imply that they have different 
epitopes, or compete with each other for antigen binding. These types of studies are 
typically performed using the antibody of interest and a well-characterized antibody with 
a known antigen binding site. Alternatively, a ligand that is known to bind the antigen 
could be used. In the event that the antibodies compete with each other for binding, one 
can approximate the epitope of the antibody of interest considering it overlaps with that 
of the competitor. Experiments using this approach are performed using a radio- or 
enzyme-labeled form of the antibody, an unlabeled form of the antibody of interest, and 
the antigen immobilized onto a solid support (Tzartos, Rand et al. 1981; Thanh, Man et 
al. 1991). Antibodies that have similar epitopes will compete and the labeled antibody 
will be displaced from the immobilized antigen. A simpler method based on this concept 
is the use of Ouchterlone gel-diffusion plates, which are used to monitor the binding of an 
antibody to a ligand and produce a thin white line that indicates formation of the immune 
complex. In the event that the competing antibodies recognize the epitope, no signal 
would be formed. Competition studies can also be performed using a Biacore approach. 
Biacore is a biosensor based on surface plasmon resonance, which utilizes an optical 
method to measure binding interactions in real time (Johne, Gadnell et al. 1993; Clement, 
Boquet et al. 2002; Wassaf, Kuang et al. 2006). These competitive approaches are 




 Taylor et al. characterized and epitope-mapped monoclonal antibodies (NS1, 
NS1, NS5, CS6, CS8, and CS9) against p22
phox
, a subunit of the integral membrane 
protein flavocytochrome b (Cyt b) that forms the catalytic core of the NADPH enzyme 
complex (Taylor, Burritt et al. 2004). The antibodies were observed to detect p22
phox
 by 
western blotting, and to identify their epitopes, peptides were generated using a phage 
display library. Of the six antibodies, three (NS2, NS5, and CS9) were observed to react 
with peptides corresponding to distinct regions of p22
Phox
 while CS6 and CS8 were found 
to bind a region previously characterized as the epitope of a discontinuous Cyt b 
monoclonal antibody, 44.1. Competition studies coupled with FRET were performed 
using these antibodies and 44.1, a previously characterized Cyt b antibody. Both CS6 and 
CS8 were observed to inhibit binding in the presence of 44.1 suggesting that all three 
antibodies recognize overlapping epitopes as indicated by phage display. CS9, NS1, and 
44.1 were found to bind simultaneously and FRET indicated that their epitopes are within 
close proximity to the 44.1 epitope, whilst NS5 was observed to bind far away. 
Furthermore, the effect of the characterized monoclonal antibodies on the catalytic 
activity of the NADPH enzyme complex was examined and CS9, NS1, NS5, CS6 and 
CS8 were found to inhibit superoxide formation. These antibodies, therefore, are 
presented as a valuable set of probes for further investigation of cytochrome b function in 






2.4.2 Protein Modification 
 
      This approach is especially useful for the identification of epitopes of a 
conformational nature that are difficult to map with simpler techniques. A range of 
techniques are employed in modifying antigens, including: protection from selective 
chemical alteration by antibody binding, site-directed mutagenesis, polymerase chain 
reaction (PCR)-random  mutagenesis, NMR-hydrogen deuterium exchange, recombinant 
deoxyribonucleic acid (DNA) methods, and homolog scanning. Several of these 
techniques are described below. 
2.4.2.1 Site-Directed Mutagenesis      
  The use of site-directed mutagenesis entails either prior knowledge of an epitope 
spanning region or scanning the primary sequence of an antibody and predicting regions 
that could potentially be involved in antibody binding. Alternatively, potential binding 
regions could be selected randomly from a primary sequence. Site-directed mutagenesis 
can be performed in multiple ways. One example features the use of recombinant 
complementary DNA (cDNA) to express antigen variants that have specific mutations. 
cDNAs of varying length containing an amino acid codon that differs from that in the 
native DNA sequence can be synthesized to produce protein variants that are different 
from the native protein. The reactivity of the antigen variants with antibodies can then be 
determined using a variety of assays. Mutations that have huge effects on binding would 
suggest that the antibody recognition site is possibly compromised. Alternatively, 
mutations can be introduced by PCR mutagenesis. The expressed proteins can then be 
tested for cross-reactivity with the antibodies to screen for epitope-negative mutants. If 
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properly designed, site-directed mutagenesis can allow for the identification of amino 
acids within the primary sequence of an antigen (Alexander, Alexander et al. 1992; 
Mengwasser, Bush et al. 2005). For antigens with a known crystal structure, site-directed 
mutagenesis can aid in confirming the specific residues that are involved in antibody 
binding (Vidali, Hidestrand et al. 2004). It is important to note that this technique is 
laborious, and would be facilitated by prior knowledge of an epitope. 
2.4.2.2 Differential Chemical Modification 
 
  The location of an epitope can also be mapped using differential chemical 
modification techniques. Chemical modification entails the use of a chemical reagent that 
targets specific amino acid side chains within a protein (see Table 2 for a list of protein 
modifying reagents) (Figure 2.2). Amino acid residues commonly targeted for protein 
modification include lysine, arginine, tyrosine, tryptophan, aspartic acid, and glutamic 
acid. Following modification, mass spectrophotometers are routinely used to analyze 
modified protein or peptide samples. In the event of successful modification; an antigen 
can then be screened for its ability to bind the antibody of interest. A number of criteria 
must be met to optimize mapping of an epitope using this method:  1) chemical 
modification must not alter protein conformation; 2) surface exposed amino acid side 
chains should be targeted for modification; 3) the modifying reagent must be specific for 
one amino acid or a group of amino acids; 4) the modified groups must be able to 
withstand the conditions required for mass spectrometry analysis (extremely acidic or 
basic). Failure of the antigen to bind to the antibody would suggest that its epitope is  
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Table 2. Reagents for the chemical modification of proteins 
      
 












Figure 2. 1 General approach for differential chemical modification of antigens 
coupled with mass spectrometry 
See text for details. This figure was reproduced with permission from Springer Science + 









likely to contain a modified residue or residues. In this event, the antigen-antibody 
complex can then be subjected to chemical modification alongside the free antigen, and 
both the eluted and free antigen can be analyzed by mass spectrometry. The antigen 
regions involved in antibody binding should in theory be shielded and therefore reactivity 
with the modifying reagent should be markedly diminished. This method is commonly 
referred to as protection from chemical alteration by antibody binding.  
2.4.2.3 Hydrogen/Deuterium Exchange  
 
      Another modification technique that bears strong similarity to modification with 
chemical reagents is hydrogen/deuterium exchange (H/D exchange) (Figure 2.3). This 
method, unlike chemical modification, is not specific towards one type or group of amino 
acids. Rather, the entire antigen is targeted for modification as the hydrogens on the 
backbone amide on the protein backbone are the groups targeted for exchange with 
deuterium, though occasional exchanges have been observed at some side chain amino 
acids. However, exchanges other than those occurring at the backbone amide hydrogens 
are excluded during analysis. There are a number of factors to consider that affect H/D 
exchange rate, namely hydrogen bonding type, solvent accessibility, and protein primary 
structure. Solvent accessibility is a key factor to consider in H/D exchange as the rate of 
exchange is typically slower at the protected buried amines than the rate of exchange of 
the bonds that are solvent exposed (Milne, Mayne et al. 1998). The kinetics of exchange 
at shielded regions versus solvent exposed regions coupled with mass spectrometry can 
used to study protein-protein interactions, including antigen-antibody interactions 








Figure 2. 2 General approach for characterizing conformational and discontinuous 
epitopes by H/D exchange and mass spectrometry. 
Antigen and antibody are individually labeled with deuterium by incubating in D2O. 
Immune complex is formed using deuterated antigen and antibody. Back exchange is 
performed on the free antigen and the immune complex. Following quenching of the 
exchange reaction, the antigen is proteolytically cleaved using immobilized pepsin at pH 
2.25. This figure was used with permission from Springer Science + Business Media. 








an antigen, the degree of H/D exchange on the free antigen is compared alongside that of 
the corresponding antigen-antibody complex.  H/D exchange is carried out by incubating 
both the free antigen and antigen-antibody individually in D2O to allow for the exchange 
of the backbone amide hydrogens with deuterium at physiological pH to maintain protein 
conformation. Both the deuterated antigen and antibody are then allowed to form an 
immune complex and subjected to back exchange so that the deuterons can be substituted 
for hydrogens, with the exception of those involved in binding and are protected by the 
antibody. The free antigen is also subjected to back exchange in preparation for 
comparison with the antigen-antibody complex. The exchange reaction is quenched at 
acidic pH values (pH 2-3) at low temperatures (0-4°C) to minimize back exchange 
reactions. For analysis, both the free antigen and antigen-antibody complex samples are 
subjected to proteolysis with pepsin (or another protease that functions at low pH values) 
and mass spectrometry is used to analyze the digested samples. Tandem mass 
spectrometry (MS/MS) can be used to identify any preserved deuterons in the sample. If 
desired, mass information can also be obtained using the intact protein.  
  Using H/D exchange followed by matrix-assisted laser desorption/ionization 
(MALDI), Baerga-Ortiz et al. identified the epitope of a monoclonal antibody against 
human thrombin (Baerga-Ortiz, Hughes et al. 2002). The epitope region, located on the 
protein surface, was found to retain deuterium in the presence of the antibody compared 
to thrombin in the absence of antibody. This discontinuous epitope was found to be 
comprised of two peptides that were localized to exosite I on thrombin and a second site 
that overlapped with the thrombomodulin binding site.  
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2.4.3 Antigen Fragmentation Methods 
 
 Epitope mapping can also be achieved by employing sequence-dependent 
methods that involve the use of antigen fragments. Fragments may take the form of 
peptide sequences that are generated by limited proteolysis, or cDNA fragmentation. This 
is a relatively simplified and straightforward approach to detecting epitopes; however, it 
applies largely to continuous epitopes (Jemmerson and Blankenfeld 1989) depending on 
the fragmentation method utilized though information pertaining to epitopes of a 
discontinuous nature can also be obtained if the epitope is comprised of regions that are 
largely continuous.  
 
2.4.3.1 Limited Proteolysis 
 
  Epitope mapping by limited proteolysis can be performed using two different 
approaches: 1) epitope excision, or 2) epitope extraction, which target either the free 
antigen or the antigen-antibody complex for proteolysis, respectively. During epitope 
excision (Figure 2.4), the antigen is bound to an immobilized antibody and subjected to 
proteolysis. In this case, the antibody plays a shielding role given that antibodies in 
general are relatively robust and resistant to proteases (Parham 1983). The parts of the 
noncovalently-bound antigen that are protected by the antibody are digested by proteases 
more slowly than the areas that are readily accessible. This results in shielding of the 
region(s) where the antigen is localized. Consequently, the peptides that constitute the 
antibody-binding site are generated at a relatively slower rate during the digestion of the 










Figure 2. 3 Epitope excision. 
See text for details. This figure was reproduced with permission from Springer Science + 









kinetics of antigen digestion can allow for the assessment of the peptides corresponding 
to the antigen epitope, and the ultimate identification of the epitope in its entirety 
(Jemmerson and Paterson 1986; Jemmerson and Blankenfeld 1989). The kinetic profile 
of antigen digestion derived either in the presence or absence of antibody can be 
generated by monitoring the molecular weight of the antigen by mass spectrometry at 
various time points, and MS/MS can be employed to determine the amino acid 
composition of the obtained peptides. For mass spectrometry analysis, the antibody-
bound peptides are obtained by separating the unbound peptides from the bound peptides. 
Alternatively, antibody-bound peptides can be analyzed directly; however, the physical 
requirements associated with mass spectrometry prevent the use of the antigen-bound 
antibody samples. 
 Contrarily, MALDI methods allow for direct placement of the immobilized 
antibody onto a MALDI plate (Parker, Papac et al. 1996; Peter and Tomer 2001; Parker 
and Tomer 2002). The bound peptide fragment can be eluted in situ by the addition of an 
acidic MALDI matrix. This method provides a straightforward and clean approach for 
sample analysis that is relatively rapid. The success of epitope mapping by this principle 
is attributed to two factors 1) the resistance of antibodies to proteolysis, especially the 
antigen-binding domains 2) the high Kd of the immunocomplex which allows for minimal 
nonspecific interactions. 
 In contrast to epitope excision in which the immunocomplex is initially formed 
and subsequently targeted for digestion, epitope extraction (Figure 2.5) features the 










Figure 2. 4 Epitope extraction. 
See text for details. This figure was reproduced with permission from Springer Science + 









method is highly dependent on a high affinity between the antibody and antigen. When 
the digested sample is applied to a column of immobilized antibody, the peptide 
containing the epitope would bind to the antibody and remain retained on the column. 
With both techniques, it is important to analyze both the eluted peptides and the unbound  
peptides present in the wash buffer in order to determine the parts of the antigen that are 
not interacting with the antibody.  
 Antibody purity is a concern in the described epitope mapping methods involving 
limited proteolysis. Some antibodies are not always available as pure samples, a result of 
being obtained from crude sources that include ascites or cell supernatants, and can 
interfere with mass spectrometry analysis and/or the immobilization of the antibody to 
microbeads. These challenges were addressed by Peter and Tomer, who optimized the 
epitope excision method by introducing indirect immunoabsorption in which an anti-Fc 
antibody can be used as a secondary antibody to capture the Fc region of the primary 
antibody (Peter and Tomer 2001). With this approach the antibody of interest can be 
enriched from a crude mixture without prior purification or immobilization of the 
proteins contained in the solution. Secondly, since the capture antibody recognizes the Fc 
portion of the primary antibody, this facilitates a desirable presentation of the primary 
antibody in which the antigen binding regions are exposed to the solution. Finally, the 
indirectly immobilized antibody is stabilized by cross-linking the primary antibody to the 
secondary antibody using a lysine specific cross-linker. Cross-linking also reduces the 
complexity of sample analysis, as derivatized lysines cannot be cleaved by lysine-specific  
proteases, and therefore limits the number of peptides that will be generated upon 
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proteolysis of the immunocomplex (Peter and Tomer 2001). 
 
2.4.3.2 Chemical Fragmentation 
 
 An alternative to limited proteolysis is chemical fragmentation. A number of 
chemicals exist that target specific amino acid residues within a protein for cleavage, 
including cyanogen bromide (methionine residues) (Houghten and Li 1983), O-
iodosobenzoic acid (tryptophan residues and tyrosines to a lesser extent) (Mahoney and 
Hermodson 1979), and 2-nitro-s-thiocyanatebenzoic acid (cysteine residues) (Stark 
1977). Following chemical fragmentation, experiments are performed to analyze the 
reactivity of the antigen fragments with the antibody. The method is analogous to that of 
limited proteolysis in that fragmentation can be performed in the presence or absence of 
antibody.  It is important to note that the conditions for chemical fragmentation are 
usually denaturing, and therefore are not ideal for discontinuous epitopes, but can be used 
to identify continuous epitopes. 
 
2.4.3.3 cDNA Fragmentation 
 
   If the antigen of interest was derived recombinantly, many other methods for 
generating antigen fragments are available. Gene-targeted random epitope libraries 
consisting of diverse peptides can be generated using DNA clones encoding the target 
antigen (Nguyen and Morris 1993). Random digests of the recombinant cDNAs can be 
performed with DNase 1, followed by cloning and expression of the cDNA fragments in 
bacteria to generate random epitope libraries that are subsequently screened with 
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antibodies by immunoblotting. Phage display methodology is another gene-targeted 
approach for epitope mapping that also entails the use of a library of epitopes (Wang and 
Yu 2004). Unlike other random peptide libraries generated by bacterial expression, a rod-
shaped virus of bacteria known as filamentous bacteriophage are utilized in displaying 
the library, and are believed to provide a better environment for folding thereby 
promoting the display of conformational epitopes. For antigen fragment or peptide 
display, mainly the phage gIII and GVIII genes encoding coat proteins have been targeted 
for genetic modification. Phage libraries are prepared by cloning small fragments of 
DNA encoding the antigen of interest into a phage expression vector consisting of a 
coding sequence for the phage coat protein allowing the protein to be displayed on 
bacteriophage. By utilizing a collection of gene fragments, the generated library is not 
largely diverse, but rather is of limited complexity and presents the native peptide 
sequence, thus, increasing the effectiveness of the method. Selection of the epitope 
presenting phage is accomplished by panning methods that are enriched for affinity 
selection. Any displayed peptides that are observed to bind to an antibody can be 
identified by sequencing the encoding insert in the genome of the phage. This approach 
has the advantage of being able to identify, not only linear, but also discontinuous 
epitopes. In theory, critical residues involved in antibody binding can be identified and 
mimotopes, which mimic discontinuous epitope structures, can also be discerned (Wang, 
Du Plessis et al. 1995; Wang and Yu 2004). This method was employed in epitope 
mapping complement component C9, a globular membrane inserting protein (Stanley and 
Herz 1987).    
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2.4.4 Synthetic Peptide-based Methods 
 
 The use of synthetic peptides that mimic parts of an antigen is an alternative 
approach to epitope mapping that is relatively rapid and practical for linear epitopes. If 
the primary structure of the antigen is known, the protein sequence can be scanned to 
generate overlapping peptides (PEPSCAN) (He, Zhou et al. 2005). The resulting peptide 
library can then be probed for binding to the respective antibody by ELISA or any solid 
phase binding platform. Furthermore, as the peptides can be synthesized automatically, 
minimal labor from the user is required.  
 In contrast, if peptide ligands are to be identified without prior knowledge of the 
antigen of interest then a combinatorial approach would have to be employed where 
arrays of individual peptides sequences are generated randomly (Houghten, Pinilla et al. 
1991). This is a de novo approach to peptide synthesis (also known as the SPOTS 
technique) that entails the synthesis of peptide mixtures with randomized positions that 
are defined from a statistical standpoint using a certain set of amino acids. To limit the 
large number of potential peptides that would be generated given the combinatorial 
nature of this approach, peptides of shorter length are favored, and a limited number of 
positions within each sequence have defined amino acids. The generated peptides are 
spotted onto a planar support (microchip) and potential epitopes are subsequently 
identified by detection of the antibody by a fluorophore-labeled secondary antibody and 
immunofluoresence microscopy. 
      In rare cases where antigens are difficult to purify, synthetic peptide-based 
methods are highly beneficial. One major limitation of this approach is that it is not 
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useful in the identification of conformational epitopes, which is the category that many 
protein epitopes fall under. As with every method, each of the aforementioned epitope 
mapping techniques has its limitations, requires a certain amount of effort, and involves a 
degree of risk depending on the rate of failure. Often multiple techniques are employed in 
epitope mapping to ensure that the observations made are unequivocal. 
 To date, a number of attempts have been made to epitope map antibodies. With 
the ever increasing need for understanding structure-function relationships, protein-
protein interactions, and vaccine development amongst other research goals, novel 
epitope mapping approaches are likely to be introduced and the existing methods will be 
optimized. Additional information, including detailed backgrounds, materials and 
applications, and stepwise protocols for each approach can be found elsewhere  (Reineke 
and Schutkowski 2009).   
 
Summary 
 In this study, epitope mapping approaches were undertaken to define the receptor 
binding region(s) in factor V that allow for its binding to and endocytosis by 
megakaryocytes. Previous studies indicate that the light chain of factor V mediates its 
endocytosis. A monoclonal antibody, E9, directed toward the light chain of factor V has 
also been observed to inhibit factor V binding and endocytosis by megakaryocytes 
suggesting that the factor V light chain region(s) recognized by this antibody is/are likely 
to be involved in receptor binding. Thus, epitope mapping studies of E9 to identify the 
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amino acid regions within the factor V antigen targeted by this antibody were performed 






















CHAPTER THREE: Studies to Identify the Factor V Residues Mediating its 
Endocytosis to Form the Unique Platelet-derived Cofactor Molecule 
 
 





















3.1 MATERIALS AND METHODS 
 
 
3.1.1 Materials Iodine-125 and the Western Lightening chemiluminescence reagent were 
obtained from PerkinElmer, Inc (Waltham, MA). Iodogen tubes were from Thermo 
Scientific (Rockford, IL). Hirudin was from Calbiochem (San Diego, CA). Vesicles 
comprised of 75% phosphotidylcholine/25% phosphotidylserine (PC/PS) were 
generously provided by Dr Kenneth Mann (University of Vermont, Burlington, VT). 
Tris-glycine gels (4-12% and 10% gradient gels) were from Invitrogen (Carlsbad, CA). 
Simplastin was purchased from Trinity Biotech (Berkley Heights, NJ). Apiezon Oil was 
from J.B Biddle Co (Blue Bell, PA). Asp-N from Pseudomonas fragi, recombinantly 
prepared Trypsin Gold (mass spectrometry grade), and ProteaseMAX, were purchased 
from Promega (Madison, WI). 
 
3.1.2 Proteins and Antibodies Human factor V was purified from pooled plasma by 
immunoaffinity chromatography and characterized as described previously (Nesheim, 
Katzmann et al. 1981). Human thrombin and factor Xa were purchased from 
Haematologic Technologies, Inc. (Essex Junction, VT). Bovine serum albumin (BSA) 
was obtained from MP Biomedicals (Solon, OH). Mouse monoclonal antibodies directed 
towards human factor V (E9 and anti-factor V #2, #17, and #9) were obtained from the 
Monoclonal Antibody Core Facility (Department of Biochemistry, University of 
Vermont, Burlington, VT, USA). Nonspecific mouse IgG (Reagent Grade) was from 
Sigma (St Louis, MO). Horse anti-mouse IgG coupled to horseradish peroxidase was 
from Jackson ImmunoResearch Laboratories, Inc (Westgrove, PA). 
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3.1.3 Cell Culture Reagents The megakaryocyte-like cell line, CMK, was obtained from 
DSMZ (Braunschweig, Germany). Fetal bovine serum (FBS), 100X penicillin (10,0000 
U/mL)/streptomycin (10,000 µg/mL) solution and 100X L-glutamine (200 mM) were all 
purchased from Invitrogen. 
 
3.1.4 CMK Cell Culture. The megakaryocyte-like cell line, CMK, originally derived 
from a megakaryoblastic leukemia patient, was cultured as described previously 
(Taniguchi, London et al. 1999). Cells were maintained in growth medium consisting of 
RPMI-1640 media supplemented with 10% FBS, 2 mM L-glutamine, and 100 U/mL 
penicillin/100 µg/mL streptomycin (CMK complete media). The cells were subcultured 
once a week (day 7) by centrifugation (250 x g, 8 min) and resuspension (1:40) in CMK 
complete media, and maintained at 37°C in an atmosphere of 5% CO2 and 99% humidity. 
The cells were utilized for experiments when they had reached a plateau in their growth 
(days 5 and 7) prior to replenishing their growth medium. Prior to experimental use,  the 
cells  were washed twice by centrifugation followed by resuspension with 5mM N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES), 0.14M NaCl, 2.7mM KCl, 12 
mM NaHCO3, 0.42mM NaH2PO4, 1mM MgCl2, pH 7.4 containing 5mM dextrose and 
0.35% bovine serum albumin, (Ca
2+
-free HTA buffer). Viability was assessed by trypan 
blue exclusion.  
 
3.1.5 Factor V Iodination. Factor V was radiolabeled as described using the Iodogen 





I) was activated in an Iodogen precoated tube by incubation for 6 min at 4°C. 
Following activation, factor V (0.5 mg) was added to the free iodine and incubated for 9 
min at 4°C. The radiolabeled factor V (
125
I-factor V) was separated from free iodine 
using gel filtration chromatography, and trifluoroacetic acid precipitation was used to 
determine the percentage of radiolabeled protein. A γ-counter (Cobra II Auto-Gamma 
Counter, Canberra-Packard, Canada, IL) was utilized for radioactivity detection. 
Subsequent to radiolabeling, the protein was analyzed by SDS-PAGE (5000 cpm/lane) 
and phosphorimaging. Its activation to factor Va was assessed by incubation of  
125
I-
factor V with thrombin overtime followed by SDS-PAGE and autoradiography as noted 
in a previously described protocol (Suzuki, Dahlback et al. 1982). 
 
3.1.6 SDS-PAGE and Phosphorimaging. Proteins diluted 1:5 in 312.5mM Tris, 25mM 
ethylenediaminetetraacetic acid (EDTA), 10% SDS, 50% glycerol, 0.05% bromophenol 
blue, pH 6.8 (5X SPB) were reduced with β-mercaptoethanol BME (5%), and separated 
by SDS-PAGE using 4-12% or 10% polyacrylamide gels following the method of 
Laemmli (Laemmli 1970). For phosphorimaging, gels were fixed with 9% acetic acid and 
18% methanol, subsequently treated with 5% glycerol, and dried under vacuum at 65°C. 
The dried gel was then exposed overnight onto a phosphorimaging screen that was 
subsequently analyzed using a Molecular Imager FX operating through the Quantity One 
analysis software v.4.6.3.  
3.1.7 Effect of Anti-factor V Antibodies on 
125
I-Factor V Binding to CMK Cells. To 
determine the ability of the factor V light chain antibodies (E9 or anti-factor V #2) to 
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inhibit factor V binding to megakaryocytes, an equilibrium binding method (Bouchard, 
Meisler et al. 2008) was utilized. CMK cells were washed two times by centrifugation 
(250 x g, 8 min) followed by resuspension in Ca
2+
-free HTA buffer prewarmed to 37°C. 




 cells/mL) were equilibrated for 10 min at 37˚C 
and 
125
I-factor V was preincubated with molar excesses of E9 (1 µM) or anti-factor V #2 
(1 µM) for 30 min. Time-dependent binding of 30 nM 
125
I-factor V to the cells was 
initiated by incubating the cells with 
125
I-factor V (-/+ E9 or anti-factor V #2). Aliquots 
(250 µL) were collected over time (0-25 min), and layered over an Apiezon A oil/n-
butylpthalate mixture (1:9, v/v; 500 µL) that was subsequently subjected to centrifugation 
in order to separate the cell bound 
125
I-factor V from the free 
125
I-factor V. The amount of 
bound factor V was determined by counting the amount of radioactivity associated with 
the cell pellets using a γ-counter. The radioactivity associated with the supernatants was 
also determined to ensure the consistency of the aliquot collecting. Specific binding was 
determined in experiments performed with under steady state conditions using 50-fold 
molar excess of unlabeled factor V to determine nonspecific binding, which was 
subtracted from total binding. For experiments in which the ability of E9 to displace 
CMK cell surface bound 
125
I-factor V (30 nM) was tested, binding was monitored from 0 
to 10 min at which time the reaction mixture was split in two, and E9 (0.1 µM) was 
added to one reaction mixture. In the second reaction mixture, Ca
2+
-free HTA served as 
the control. Aliquots were removed from both mixtures over time (15-25 min), and bound 
125
I detected as described above. 
 In other experiments, varying concentrations of E9 (0, 0.01, 0.02, 0.05, 0.1, 0.2, 
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0.5, 1.0, 2.0 µM) were incubated with 30 nM 
125
I-factor V for 30 min at 37°C. Binding 




-free HTA, and the 
samples were incubated for an additional 30 min. Bound 
125
I-factor V was detected ad 
described above. 
 
3.1.8 Effects of E9 and Anti-factor V #2 on Factor V Cofactor Activity. Factor V 
cofactor activity was measured using a plasma-based clotting assay. A standard curve 
was generated by making dilutions (1:4 to 1:250) of a normal human plasma pool in 20 
mM HEPES, 150 mM NaCl, pH 7.4, containing 5 mM CaCl2, and 0.1% PEG 
(HBS/Ca
2+
/PEG) Each dilution was mixed with an equal volume of plasma made factor 
V-deficient by anti-factor V immunoadsorption, and clot formation was initiated by the 
addition of Simplastin, which contains relipidated tissue factor and Ca
2+
. The factor V 
activity of each dilution versus the clot time was plotted on a semi-logarithmic scale with 
the assumption that normal human plasma contains 1 U factor V/mL (7-10 µg factor 
V/mL). To assess the function of factor V in the presence of E9 and anti-factor V #2, a 
clotting assay was performed using factor V (1:10 dilution) that was preincubated with 
30-fold molar excesses of the antibodies. A non-specific mouse IgG in addition to factor 
V light (anti-factor V #9) and heavy (anti-factor V #17) chain antibodies known to not 
affect prothrombinase complex assembly were utilized as controls. The equation 
generated with the standard curve was used to extrapolate the factor V activity in the 




3.1.9 Western Blotting of Factor V. For epitope characterization of the factor V 
antibodies, samples of factor V and Va were separated by SDS-PAGE using 4-12% or 
10% gels under reducing or non-reducing conditions and transferred onto a nitrocellulose 
membrane according to the method of Towbin et al. (Towbin, Staehelin et al. 1979), 
Briefly, nonspecific binding sites were blocked with 5% nonfat dry milk in 20 mM Tris, 
0.15 M NaCl, pH 7.4 (TBS) containing 0.05% Tween 20 (TBS-T) overnight at 4°C.  
Factor V and Va were probed with each of the factor V light chain antibodies, E9, anti-
factor V #9, and #2 (5 µg/mL each), in TBS-T for 1hr at ambient temperature. Following 
three washes with TBS-T, bound antibody was detected using a horse anti-mouse IgG 
secondary (0.2 µg/mL) conjugated to horseradish peroxidase, followed by 
chemiluminescence.  
 
3.1.10 Factor Xa Proteolysis of Factor Va. Factor Va was subjected to proteolysis by 
factor Xa as previously described (Tracy, Nesheim et al. 1983). Factor V (1μM) 
containing trace 
125
I-factor V (5000 cpm/µL) in HBS/Ca
2+
/PEG was activated with 20 
nM thrombin (10min, 37˚C) as described by Suzuki et al. (Suzuki, Dahlback et al. 1982). 
Hirudin (30 nM) was subsequently added in order to inhibit further thrombin activity. 
Factor Va (60 nM) was incubated with 20 µM PC/PS vesicles for 15 min at 37˚C. 
Following incubation, 52 nM Xa was added and aliquots removed over time (0-60 min). 
The reaction was quenched by the addition of 5X SPB to a final concentration of 1X. To 
analyze cleavage of factor V, the collected samples were analyzed by SDS-PAGE and 
autoradiography as described. In some experiments, factor Va was pre-incubated with 0.1 
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µM E9, anti-factor V #2, a non-specific mouse antibody, anti-factor V #9, or anti-factor 
V #17 for 30 min prior to cleavage of factor Va with factor Xa. Densitometric analyses 
were performed using the Quantity One software v.4.6.3. 
   
3.1.11 Immunoprecipitation of Factor Xa-Cleaved Factor Va by E9. 
125
I-factor Va 
was cleaved by factor Xa as described above. E9-coupled to sepharose, prepared as 
previously described (Katzmann, Nesheim et al. 1981; Nesheim, Katzmann et al. 1981), 





) by centrifugation (3X, 2000 x g, 3 min), followed by resuspension. Factor 
Xa-cleaved 
125
I-factor Va was incubated with the immobilized E9 for 2 hours at 4°C with 
gentle rocking. Unbound protein was removed by centrifugation as described above. The 
resin was washed with HBS/ Ca
2+ 
or 20 mM Tris, 1.65 mM NH4Cl, 1 mM benzamidine, 
pH 7.4 (high salt buffer)  until the OD ≤ 0.01. Bound protein was eluted with 62.5mM 
Tris, 5mM EDTA, 2% SDS, 10% glycerol, 0.01% bromophenol blue, pH 6.8 (1X SPB). 
Additional EDTA (2.5 mM) was added to ensure that the Ca
2+
 was chelated and to 
promote the dissociation of the heavy and light chain. The eluted samples were analyzed 
by SDS-PAGE and autoradiography as described. In some reactions, PC/PS vesicles were 
disrupted by the addition of 10% nonyl phenoxypolyethoxylethanol-40 (NP-40), and 1% 
Triton X-100 (2 min, 37°C) prior to the addition of immobilized E9.  
 
3.1.12 Solid Phase Binding Assay. A solid phase binding assay for competition 
experiments was designed using 96-well microtiter plates. The factor V light chain 
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monoclonal antibody, E9 (33.3 nM), in 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl, 
pH 7.4 (PBS), was immobilized onto the microwells by incubation at 4°C overnight. The 
plates were washed three times with PBS, and blocked with 5% BSA in PBS for 1 hr at 
37°C. To confirm that the immobilized E9 could interact with factor V, the binding of 
varying concentrations of
 125
I-factor V (0, 15.2, 30.3, 60.6, 90.9, 121.2, 151.5, and 227.3 
nM) to E9 was measured following a 2 hr incubation at RT with gentle shaking. The 
unbound proteins were removed by aspiration and the wells were washed with PBS three 
times. Bound material was eluted with 1N NaOH, and aliquots of the eluted samples were 
counted using a γ-counter. To confirm the specificity of E9 in the assay, 125I-prothrombin 
was substituted for 
125
I-factor V. As the amount of protein bound in a solid phase assay is 
known to increase proportionally with the amount of IgG coated on the wells, varying 
concentrations (0, 3.3, 6.7, 13.3, 20.0, 26.7, and 33.3 nM) of E9 were also used to coat 
the wells to determine an optimal concentration of E9 for the assay.   
 For the competition assay, initial experiments were performed to determine the 
amounts of factor V needed to displace E9-bound 
125
I-factor V by using a fixed 
concentration of 
125
I-factor V (15.2 nM), and unlabeled single chain factor V at various  
concentrations (0, 3.8, 7.6, 30.3, 90.9, 151.5, 303.0, and 454.5 nM) as a competitor. To 
assess the ability of various forms of unlabeled factor V (factor Va, factor Xa-cleaved 









3.1.13 Proteolysis of Factor V with Asp-N and Trypsin. 
125
I-Factor V was digested 
with Asp-N or trypsin following the in-solution digestion method described per the 
manufacturer’s instructions. Prior to digestion with Asp-N, 125I-factor V was subjected to 
reduction and alkylation by incubation with dithiothreitol (DTT) for 20 min (50-60°C), 
followed by incubation with 15 mM iodoacetamide (15 min, ambient temperature, in the 
dark). The digestion enhancer, ProteaseMAX surfactant (1%), was added to solubilize the 
protein and facilitate digestion. Lastly, Asp-N was added to a final protease:protein ratio 
of 1:20 (w/w) and the sample was incubated for 18 hr. The protease was quenched either 
by heating or with the use of an endoproteinase specific inhibitor. In digestions 
performed with trypsin, 
125
I-factor V was incubated with trypsin under nondenaturing 
conditions at in a final protease:protein ratio of 1:20 (w/w) for 1 hr at 37°C. The reaction 
was terminated with the use of a serine protease inhibitor cocktail. For analysis, the 
digested proteins were separated by SDS-PAGE (4-12% gradient gels), and silver-stained 










3.2.1 The Effect of Various Factor V Light Chain Antibodies on 
125
I-factor V Binding 
to CMK Cells 
 
  As previous studies have demonstrated that factor V endocytosis by 
megakaryocytes is inhibited by a number of monoclonal antibodies directed against the 
human factor V light chain (anti-factor V #2, E9, and anti-factor V #5), subsequent analyses 
were performed to confirm that these antibodies blocked factor V binding as well. Time-
dependent binding of factor V to the megakaryocyte-like cell line, CMK, was studied in the 
absence of Ca
2+
, which is not required for binding of factor V to the cell surface but 
absolutely necessary for the clathrin-mediated endocytosis of factor V in a minimally altered 
system (Bouchard, Meisler et al. 2008). Previous observations demonstrate that factor V 
binding to CMK cells under this condition is mediated by a two receptor system, is specific, 
time- and concentration-dependent, reversible, and saturable (Bouchard, Meisler et al. 
2008). To determine the effects of E9 and anti-factor V #2 on time-dependent binding, a 
plasma concentration of 
125
I-factor V (30 nM) was treated with 10-fold molar excesses of 
the antibodies, and binding to the CMK cell surface was assessed. Compared to binding in 
the absence of antibody (Figure 3. 1, blue diamonds), binding of 
125
I-factor V to the CMK 
cell surface in the presence of E9 was inhibited by ~75% (Figure 3. 1, red squares). In 
contrast, despite having previously shown to inhibit factor V endocytosis, anti-factor V #2 
had no effect on 
125
I-factor V binding (Figure 3. 1, green circles). As an additional control, 
time-dependent binding was monitored in the presence of a nonspecific mouse IgG, which 







Figure 3. 1 Effect of monoclonal factor V light chain antibodies on factor V binding. 
Time-dependent binding of factor V was monitored in the absence or presence of IgG (E9 
or anti-factor V #2). Factor V (30 nM) was pre-incubated with buffer or 10-fold molar 
excesses of IgG in Ca
2+
-free HTA (30 min). Binding was initiated by the addition of 
CMK cells (2x10
6
 cells/mL). Each point represents the mean ± standard deviation (SD) 
of two experiments performed in duplicate. Curves were fit by eye and drawn using 








3.2.2 E9 is a Potent Inhibitor of Factor V Binding to the CMK Cell Surface 
 
 The inhibition of factor V binding to the CMK cell surface by E9 was further 
investigated by monitoring the binding of 
125
I-factor V in the presence of varying 
concentrations of E9. For these experiments, binding of 
125
I-factor V at each E9 
concentration was determined at 30 min, by which time the binding of factor V to the 
megakaryocyte cell surface is typically at steady state. Under these conditions, the data 
indicate that 
125
I-factor V binding decreases steadily with increasing concentrations of 
E9, and inhibition was nearly complete at 0.1 µM E9 (Figure 3. 2).  
 The effect of E9 on factor V binding to CMK cells was further characterized to 
determine if it inhibited binding to one or both receptors by assessing its ability to 
displace 
125
I-factor V from the CMK cell surface. As shown in Figure 3. 3, following the 
addition of E9, a decrease in binding was observed with ~70% of the cell surface bound 
factor V dissociated by 25 min as compared to binding in the absence of E9.  
 
3.2.3 Western Blotting Analyses of Factor V using Various Anti-Factor V Light 
Chain Antibodies 
 
 To determine the nature of the epitope recognized by E9 and anti-factor V #2, 
western blotting analyses were performed using intact and thrombin-activated factor V 
under reducing conditions (Figure 3. 4). Another anti-factor V antibody, #9, which is 










Figure 3. 2 Inhibition of factor V binding to the megakaryocyte cell surface by E9. 
125
I-factor V (30 nM) was pre-incubated with varying concentrations of E9 (0, 0.01, 0.02, 
0.05, 0.1, 0.2, 0.5, 1.0, 2.0 µM) prior to the addition of CMK cells. After 30 mins, 
binding was assessed by collecting equivalent aliquots (150 µL) from each sample, 
separating the cell-surface bound protein from the unbound protein by centrifugation 
through oil as described, and determining the amount of radioactivity associated with the 
cell pellets. Nonspecific binding was estimated in a parallel reaction in the presence of a 
50-fold molar excess of unlabeled factor V. Specific binding was determined by 
subtracting nonspecific binding from total binding. The data represent the mean ± SD of 
the specific binding from two experiments performed in duplicate. The curve was fit by 













Figure 3. 3 Displacement of factor V from the megakaryocyte cell surface with E9. 
125
I-factor V (30 nM) binding to the CMK (2x10
6
 cells/mL) cell surface was monitored 
over time in the absence of IgG. At 10 mins following the initiation of binding, the 
reaction was evenly divided and added to either a Ca
2+
-free HTA control or 1.5 µM E9.  
Binding was further monitored by the collection of aliquots at 15, 20, and 25 min. Each 
data point represents the mean ± SD of two experiments performed in duplicate. The 











Figure 3. 4 Western blotting of intact and thrombin-activated factor V with various 
anti-factor V light chain antibodies. 
Factor V (1 µM) was activated to factor Va by thrombin (2 U/mL, 10 min, 37°C). 
Thrombin activity was quenched with hirudin (30 nM). Factor V and factor Va samples 
were diluted 1:5 in 5X SPB and subjected to SDS-PAGE under reducing conditions on 4-
12% gels. Resolved proteins were transferred onto a nitrocellulose membrane, and 
subjected to western blotting as described. Single chain factor V and factor Va were 
probed using anti-factor V light chain antibodies, #2 (Panel A), #9 (Panel B), and E9 
(Panel C). The numbers on the left indicate the migration of the molecular weight 
markers. NOTE: The data shown in panel A) were obtained from an experiment 







included as a control. Both anti-factor V #9 and #2 recognize intact factor V and the 
factor V light chain. Similar results were obtained under non-reducing conditions (data 
not shown) These data suggest that these antibodies are directed against a linear epitope 
within the factor V light chain and suggest that the epitopes are not conformation 
specific. The anti-factor V antibody, E9, in contrast, did not recognize either factor V or 
Va. As no reactivity was observed under non-reducing conditions either, these data 
suggest that E9 is directed against a discontinuous and/or conformation-dependent 
epitope.  
 
3.2.4  Factor V Cofactor Activity is Not Perturbed by E9 
 
 To examine factor V function in the presence of E9, a plasma clotting assay was 
performed. Factor V was used at 1/10 its normal plasma concentration, which results in 
an average clot time of 30 sec. In the presence and absence of E9, clot times in the range 
of 29-30 sec were observed, as were the clot times obtained in the presence of control 
antibodies. These results suggest that E9 does not affect factor Va binding to PC/PS 
vesicles or its cofactor activity in Prothrombinase. 
 
3.2.5 E9 Does Not Affect Cleavage of Factor Va by Factor Xa at Arg1765 of the 
Light Chain 
 
 Previous studies have demonstrated that the light chain of bovine and human 
factor V is cleaved by factor Xa at Arg1765 into two fragments of ~30 and 48/46 kDa 
(residues 1546-1765 and 1766–2196, respectively) (Tracy, Nesheim et al. 1983; 
Odegaard and Mann 1987; Thorelli, Kaufman et al. 1997) (Figure 3. 5A). In an attempt to 
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utilize factor V light chain fragments in epitope mapping studies, initial experiments were 
performed to examine the cleavage pattern of human factor Va with factor Xa under 
conditions previously described for the bovine molecule (Tracy, Nesheim et al. 1983). 
The proteolysis of thrombin-activated 
125
I-factor V with factor Xa resulted in the 
generation of two light chain fragments of 48/46 and 30 kDa (Figure 3. 5). In addition, 
cleavage at Arg1765 was observed to occur at a relatively faster rate in the presence of 
PC/PS vesicles as compared to cleavage performed in the absence of a membrane surface 
(data not shown). To test the ability of the factor V light chain antibodies to detect the 
factor Xa-generated products of factor Va, western blotting analysis was performed with 
anti-factor V #2, but not E9, as this antibody does not react with factor V under 
denaturing conditions. In comparison to anti-factor V #9, which detects the 48/46 kDa 
fragment, neither the 30 nor the 48/46 kDa cleavage products were detected by anti-factor 
V #2 (Figure 3. 6) suggesting that its epitope encompasses Arg1765 and that this 
antibody may inhibit cleavage of factor Va by factor Xa.  
 To assess this possibility, additional experiments were performed to determine 
whether the factor Xa cleavage site (Arg1765) within the light chain region of factor V is 
protected by the association of anti-factor V #2 with the light chain. 
125
I-factor V was 
subjected to proteolysis with factor Xa in the absence or presence of factor V antibodies, 
including anti-factor V #2, #9, #17, and E9 (Figure 3. 7A). The presence of anti-factor V 
#2 inhibited factor Va cleavage by factor Xa. After a 10 min incubation in the presence of 
#2, minimal amounts of the 48/46 kDa cleavage products were present. Unlike anti-factor 











Figure 3. 5 Factor Va cleavage by factor Xa on PC/PS vesicles. 
Panel A) Factor Xa cleaves factor Va at Arg1765, resulting in the production of an N-
terminally-derived 30 kDa fragment, and a differentially glycosylated 48/46 kDa 
fragment derived from the C-terminal end of the factor V light chain. Panel B) 
Proteolysis of thrombin-activated factor Va by factor Xa was monitored over time. 
125
I-
Factor Va (60 nM) was pre-incubated on 20 µM PC/PS vesicles for 15 min, and 
following the addition of factor Xa (52 nM), aliquots were collected and quenched in 5X 
SPB at 4°C. The proteins were separated by SDS-PAGE (5000 cpm/lane) and analyzed 


































            
 
    
 
Figure 3. 6 Anti-factor V #2 does not detect factor Xa-catalyzed cleavage products of 
factor V by western blotting 
Thrombin-activated factor Va was cleaved at Arg1765 by factor Xa as described. Intact 
factor Va light chain and light chain cleavage products were probed by western blotting 
with anti-factor V #9 and #2. The numbers in the center indicate the migration of the 
molecular weight markers. The positions of the intact light chain and the 48/46 kDa 














Figure 3. 7 E9 does not affect cleavage of the factor Va light chain at Arg1765. 
Panel A) Cleavage of 
125
I-factor Va bound to synthetic phospholipid vesicles by factor 
Xa in the presence and absence of antibodies was assessed at 0 min (black bars) and 10 
min (grey bars) by autoradiography as described. The light chain (FV LC), heavy chain 
(FV HC), and B domain of thrombin-activated factor Va are indicated, as are the 48/46 
kD and 30 kD factor Xa cleavage products. The migration of the molecular weight 
markers is indicated on the left of each panel. The red box highlights the results obtained 
in the presence of E9 and anti-factor V #2. Panel B) Densitometric analyses of the 
protein bands visualized by phosphorimaging was performed as described. The bars 
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the control antibodies (a non-specific mouse IgG, anti-factor V #9 and # 17). 
Densitometry analysis of the phosphorimaging data (Figure 3. 7B) indicated that similar 
to the cleavage of the factor V light chain in the presence of a factor V heavy chain 
antibody, and a nonspecific mouse antibody, only ~40% of the factor V light chain was 
retained in the presence of E9 at 10 min. In contrast, ~80% of the light chain was retained 
in the presence of anti-factor V #2. These data collectively suggest that the E9 
recognition site/epitope on the factor Va light chain is not localized around Arg1765. 
 




I-factor Va (Figure 3. 8A, lane 1a) was cleaved with factor Xa (Figure 3.8A, 
lane 2) and immunoprecipitated with E9 to determine which light chain fragment E9 
binds. Both the 48/46 and 30 kDa cleavage products were present in the starting material 
(Figure 3. 8A, lane 2), and each elution (Figure 3. 8A, lanes 4 and 5). Not unexpectedly, 
the B domain (150 kDa) was not retained on the column and was present in the 
flowthrough (Figure 3. 8A, lane 3). These data suggest that E9 is binding to an epitope 
comprised of residues from both the 30 kDa or the 48/46 kDa fragment that are within 
close proximity when the protein is in its native conformation. Alternatively, it can be 
hypothesized that the region detected by E9 may be localized within either the 30 kDa or 
the 48/46 kDa fragment, and that these fragments are noncovalently associated. To test 
this hypothesis, high salt buffer was used in performing washes after 
immunoprecipitation with E9 to disrupt any noncovalent interactions contributing to the 





Figure 3. 8 Immunoprecipitation of factor Xa-cleaved factor Va with E9. 
 
125
I-factor Va was cleaved with factor Xa, and the proteolytic products 
immunoprecipitated with E9. Panel A ) Lanes 1a (lighter exposure), and 1b illustrate 
thrombin-activated factor V prior to cleavage with factor Xa (lane 2). Lane 3 depicts the 
flowthrough and lanes 4 and 5 depict the products pulled down by E9. In this particular 
experiment, washes were performed using HBS/Ca
2+
. Panel B) To disrupt potential 
noncovalent associations, high salt washes were performed. The lanes are numbered 






elution (Figure 3. 8B, lanes 4 and 5). 
 As PC/PS vesicles provided a membrane surface for factor Va prior to factor Xa 
cleavage and incubation with immobilized E9, it was also hypothesized both the 48/46 
and 30 kDa fragments were retained on the vesicle surface following factor Xa cleavage. 
Thus, upon immunoprecipitation, both fragments would be isolated as E9 does not affect 
factor Va’s interaction with the vesicle surface. However, disruption of the vesicles with 
detergents prior to the addition of E9 resulted in an elution pattern identical to that 
obtained when the reaction contained intact PC/PS vesicles (data not shown).  
 As the heavy chain (105 kDa) fragment of factor V also undergoes cleavage, 
though at a slower rate compared to the light chain, the cleaved factor Va samples were 
also subjected to western blotting analysis using a factor V antibody directed towards its 
heavy chain, anti-factor V #17, to determine if either of the observed products were 
heavy chain- derived. By western blotting analysis neither the 48/46 nor the 30 kDa 
fragments were detected by the antibody. Thus, it appears that both of these products are 
specific to the light chain (data not shown).  
 
3.2.7 Development of a Solid Phase Binding Assay to Probe Interactions Between E9 
and Factor V. 
 
 A solid phase assay was developed in order study the ability of factor V fragments 
generated by proteolysis to displace intact factor V from E9. Initial experiments were 
performed to identify appropriate concentrations of E9 and unlabeled factor V to use. 
Binding of increasing concentrations of 
125
I-factor V to a fixed concentration of 
immobilized E9 was specific, concentration-dependent, and saturable (Figure 3. 9A). The 
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specificity of E9 was confirmed with the use of 
125
I-prothrombin, and linear, non-
saturable binding was observed. In order to determine an appropriate concentration of E9 
for the assay, the amount of antibody bound to the plate was varied and its binding to a 
fixed concentration of 
125
I-factor V determined (Figure 3. 9B). Under these conditions, 
125
I-factor V binding was saturable and dependent upon the concentration of E9. Based 
on the results of these experiments, E9 and 
125
I-factor V were used at concentrations of 
3.33 nM, and 15.2 nM, respectively. 
 Preliminary experiments were performed using unlabeled single chain factor V to 
test its ability to displace 
125
I-factor V from immobilized E9, and to determine optimal 
concentrations of competitors that result in displacement for utilization in subsequent 
experiments. Incubation of 
125
I-factor V bound to immobilized E9 with varying 
concentrations of single chain factor V resulted in a steady, concentration-dependent 
decrease in bound 
125
I-factor V that correlated with the concentration of unlabeled factor 
V (Figure 3. 10). At concentrations of unlabeled single chain factor V ≥151.1 nM, no 
significant difference was observed with respect to the amount of 
125
I-factor V bound.  

























Figure 3. 9 Titration of factor V and E9 in a solid phase binding assay. 
125
I-factor V and E9 were varied to determine appropriate concentrations to utilize for the 
assay. Panel A) Immobilized E9 (151.5 nM) was incubated with various concentrations 
of radiolabled factor V (0-230 nM) (blue line). Binding specificity was confirmed with 
the use of varying concentrations of 
125
I-prothrombin (red line). Panel B) A fixed amount 
of 
125
I-factor V (15.2 nM) was incubated with varying concentrations of E9 (0, 3.3, 6.7, 
13.3, 20.0, 26.7, and 33.3 nM). The data points represent mean ± SD of two experiments 





























Figure 3. 10 Displacement of E9-bound factor V with unlabeled single chain factor 
V. 
Panel A) Schematic of the competitive solid phase binding assay. See text for details 
Panel B) The ability of single chain factor V to displace E9-bound 
125
I-factor V was 
assessed using a fixed concentration of 
125
I-factor V (15.2 nM) and E9 (3.33 nM), and 
varying concentrations of single chain factor V. 
125
I-factor V binding was monitored as 
described. Bars represent mean ± SD of two experiments performed in duplicate. Curves 





























3.2.8 Displacement of E9-bound 
125
I-factor V with Various Factor V Proteolytic 
Fragments 
 
 This highly sensitive assay was subsequently used to identify the ability of 
various factor V proteolytic fragments to compete with
 125
I-factor V for E9 binding. In 
initial experiments, the ability of factor V, thrombin-activated factor V, and factor Xa- 
cleaved factor Va to displace 
125
I-factor V bound to immobilized E9 was assessed.  Each 
competitor resulted in an ~75-85% decrease in bound 
125
I-factor V suggesting that the E9 
epitope is not altered/destroyed by these cleavages (Figure 3.11). This observation is 
consistent with the immuprecipitation data indicating that E9 bound both intact factor Va 
and factor Xa-cleaved factor Va. Factor Xa-cleaved factor Va was observed to have the 
most substantial effect on bound 
125
I-factor V as ~86% of the protein was displaced. 
These data strongly suggest that cleavage results in presentation of the epitope in a more 
favorable conformation for E9 binding. 
 Additional experiments were performed using fragments of factor V generated 
with the proteases, Asp-N or trypsin, by limited proteolysis under non-denaturing 
conditions. Treatment of factor V with each of these proteases resulted in an increase in 
the appearance of lower molecular weight proteins followed by a decrease over time as 
illustrated by SDS-PAGE and silver staining (Figures 3.12A and 3.13A). Neither the 
Asp-N- (Figure 3.12B) nor the trypsin- (Figure 3.13 B) derived factor V fragments 
displaced bound 
125
I-factor V in the solid phase binding assay. Collectively, the data 
suggest one or both of the following scenarios: 1) the E9 epitope is not retained in factor 







Figure 3. 11 Displacement of E9-bound factor V by factor Va and factor Xa-cleaved 
factor Va. 
The ability of various forms of factor V to compete with 
125
I-factor V bound to 
immobilized E9 was examined using a solid phase binding assay. Ten-fold molar 
excesses of single chain factor V (black bar), factor Va (blue bar), and factor Xa-cleaved 
factor Va (green bar) were incubated with a fixed concentration of 
125
I-factor V bound to 
immobilized E9 for 2 hr at ambient temperature. Bound protein was eluted and detected 
as described. The red bar depicts binding of 
125
I-factor V in the absence of an added 














Figure 3. 12 Effect of Asp-N-derived factor V fragments on factor V binding to E9. 
Factor V was subjected to partial proteolysis with Asp-N, under non denaturing 
conditions, at a final protease to protein ratio of 1:20. Aliquots were collect over time (0-
18 hr), resolved by SDS-PAGE and silver stained (Panel A) as described. The arrows to 
the right of the panel depict various factor V species. Panel B) Factor V fragments 
generated with Asp-N at a ten-fold molar excess were incubated with 
125
I-factor V bound 
to immobilized E9 for 2 hr at ambient temperature. Displacement was assessed as 
described. Data represent mean ± SD of two experiments performed in duplicate. The 
data are depicted as follows: No added factor V (red bar), single chain factor V (black 



























Figure 3. 13 Effect of trypsin-derived factor V fragments on factor V binding to E9. 
Factor V was subjected to partial proteolysis with trypsin, under non denaturing 
conditions, at a final protease to protein ratio of 1:20. Similar to proteolysis performed 
with Asp-N, aliquots were collect over time (0-60 min), resolved by SDS-PAGE, and 
silver stained (Panel A) as described. The arrow to the right illustrates the single chain 
factor V species. Panel B) Displacement experiments with the trypsin-generated factor V 
fragments were performed as described for Asp-N in Figure 3. 13. Data represent mean ± 
SD of two experiments performed in duplicate. The data are depicted as follows: No 
added factor V (red bar), single chain factor V (black bar), and trypsin-derived factor V 











                              





































           Factor V binding to and endocytosis by the megakaryocyte two receptor system 
to form the unique platelet-derived cofactor molecule appears to be mediated by the 
factor V light chain. In this study, the role of the light chain in factor V endocytosis by 
megakaryocytes was further addressed, with the primary focus being to specifically 
identify the amino acid regions within the factor V light chain. The monoclonal anti-
factor V light chain antibody, E9, which inhibits both the endocytosis and binding of 
factor V by megakaryocytes, also displaced bound 
125
I-factor V by ~70%. Based on the 
two receptor model for factor V endocytosis this suggests that E9 is inhibiting the 
interaction of factor V with the unknown factor V receptor or both receptors. To 
differentiate among these scenarios, a protein that antagonized LRP-1/ligand interactions, 
RAP, (Herz, Goldstein et al. 1991; Bu and Rennke 1996; Andersen, Christensen et al. 
2000) can be utilized in 
125
I-factor V displacement studies. If E9 is affecting binding to 
the factor V receptor alone, then addition of RAP will inhibit factor V binding to LRP-1 
and increase the level of 
125
I-factor V displacement. If E9 is affecting binding to both 
receptors, no difference in displacement would be observed in the presence of E9 alone 
versus E9 with added RAP. 
 To date, several phospholipid binding sites within the light chain of factor V have 
been identified and include: residues 1667-1765 (A3 domain) (Kalafatis, Jenny et al. 
1990), Tyr1956, Leu1957, Arg2023, and Arg2027 (C1 domain) (Saleh, Peng et al. 2004), 
and the Trp2063 and Trp2064 (C2 domain) (Adams, Hockin et al. 2004). Adams et al. 
solved the crystal structure of the bovine APC-inactivated factor Va, factor Vai, which 
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corroborated some existing data on the membrane binding sites of the factor V light chain 
by showing that the C2 domain featured a common beta barrel structure with three long 
loops protruding from one end, two of which contain water-exposed hydrophobic 
residues that are believed to penetrate membranes.  The fact that E9 did not affect factor 
V cofactor activity in a plasma-based clotting assay suggests that the factor Xa sites 
mediating its binding to factor Xa, and the lipid membrane surface are likely to be 
excluded from the epitope. 
 In addition, Steen et al. identified a His1683 residue localized within the A3 
domain of the factor V light chain that is implicated in factor Xa binding (Steen, 
Villoutreix et al. 2002). Under certain conditions, factor Va bound to PC/PS vesicles or 
the platelet surface is cleaved by factor Xa forming light chain fragments of 48/46 
(residues 1766-2196, A3, C1 and C2 domains) and 30 kDa (residues 1546-1765, A3 and 
C1 domain) (Tracy, Nesheim et al. 1983; Odegaard and Mann 1987; Thorelli, Kaufman 
et al. 1997). In the presence of E9, cleavage was unaffected. In comparison, cleavage was 
reduced in the presence of anti-factor V #2. Furthermore, it is unlikely that the E9 epitope 
is localized around the factor Xa cleavage. This was confirmed in subsequent 
experiments using a competitive, solid phase assay and immunoprecipitation, which 
suggested that the E9 epitope encompasses both fragments or is localized on one of the 
light chain fragments and these fragments are noncovalently-associated. Indeed, Tracy et 
al. observed that factor Xa-cleaved factor Va retains its activity in the Prothrombinase 
complex assembled on platelets (Tracy, Nesheim et al. 1983) suggesting that the 
fragments remain associated on the membrane surface. A similar observation was also 
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made by Thorelli et al. using synthetic phospholipid vesicles. In this study, attempts to 
disrupt noncovalent interactions between the fragments had no effect on E9 recognition.   
 Further antigen fragmentation using Asp-N and trypsin coupled with the solid 
phase assay was also attempted. These experiments were performed under limited 
proteolysis and non-denaturing conditions to generate longer polypeptides that may retain 
their native conformation. However, the peptides produced with Asp-N and trypsin did 
not compete with 
125
I-factor V for E9 binding suggesting that proteolysis is destroying 
the epitope by cleavage or the resulting peptides are not retaining their native forms.  
 In conclusion, this study describes the first attempt at epitope mapping an 
antibody, E9, that inhibits the binding and endocytosis of factor V by megakaryocytes. 
The combined observations suggest that E9’s epitope is conformational, specific, and 
extremely labile. While no definitive conclusions can be made regarding the regions of 
factor V that form E9’s epitope of factor V that form E9’s epitope, these efforts have 
resulted in the production of a solid phase binding assay that can be used in future 
studies.  












 The major objective of this study was to epitope map E9, a factor V light chain 
antibody, which has been observed to inhibit factor V binding to and endocytosis by 
megakaryocytes. This study has shown that the E9 epitope is conformation-
dependent/discontinuous and extremely labile. However, further studies failed to define 
what region(s) of the factor V light chain is/are recognized by E9. 
 In experiments using factor Xa–cleaved factor Va, E9 immunoprecipitated both 
the 48/46 and 30 kDa fragments suggesting that the light chain fragments are 
noncovalently associated or that E9’s epitope comprises both fragments. However, it is 
likely that the products are noncovalently associated as was shown by Tracy et al. in the 
bovine system (Tracy, Nesheim et al. 1983; Thorelli, Kaufman et al. 1997). To confirm 
this, the light chain antibody, anti-factor V #9, which detects the 48/46 kDa light chain 
fragment could be employed in a modification of the solid phase binding assay where 
wells coated with anti-factor V #9 versus E9 could be used to detect cleaved 
125
I-factor 
Va. Following extensive washing to remove unbound fragments, phosphorimaging can be 
used to detect that which remains bound to the antibody. The detection of the isolated 
48/46 kDa fragment only by anti-factor V #9 would suggest that the fragments are not 
noncovalently-associated. This would imply that E9 recognizes both fragments. 
Alternatively, in the event that the fragments are noncovalently associated, further 
experiments would have to be performed to separate the fragments. In studies examining 
the proteolysis of factor Va by factor Xa, Odegaard et al. describe the 48/46 and 30 kDa 
fragments as being “strongly noncovalently associated,” and used high performance 
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liquid chromatography (HPLC) to isolate each fragment (Odegaard and Mann 1987). As 
it is clear that E9’s epitope is not only conformation-dependent, but extremely labile, 
another approach would have to be explored for our purposes.  
 A competitive solid phase assay was developed in this study that can be exploited 
to further address the localization of the E9 epitope, and for future epitope mapping 
studies of other factor V antibodies (e.g., anti-factor V #5). In this competitive assay, ten-
fold molar excesses of the competitors were utilized. Future experiments should be 
performed with >ten-fold excess of competitor as the polypeptides that were generated 
may have lower binding affinities relative to the intact protein. Additionally, the use of 
other proteases, such as Lys C or chymotrypsin to generate fragments of factor V may 
yield useful information. Alternatively, the solid phase assay could be utilized in 
experiments designed to identify the E9 epitope by epitope excision as described in 
Chapter 2. As a control, duplicate experiments could be performed using radiolabeled 
factor V to confirm retention of factor V fragments on the antibody. 
 The presented data indicate that anti-factor V #2, which was previously observed 
to inhibit factor V endocytosis, had no effect on factor V binding to megakaryocytes. The 
original hybridoma clone of the anti-factor V #2 antibody could be obtained and used to 
produce a new batch of the antibody. Its effect on binding and endocytosis could then be 
tested to determine if the newly prepared antibody behaves as expected. The fact that the 
antibody was observed to inhibit cleavage by factor Xa could suggest that its epitope 
spans Arg1765. Interestingly, the region 
(DEKKSWYYEKKSRSSWR/LTSSEMKKSHEFHAINGMIY), surrounding this 
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cleavage site (R/L) features a marked presence of lysine residues (shown in blue), which 
have been shown to mediate the binding of other ligands to LRP-1 (Bovenschen, Boertjes 
et al. 2003; Ranganathan, Cao et al. 2011). Furthermore, there is a high degree of 
sequence identity in the amino acids surrounding the factor Xa cleavage site in addition 
to conservation of lysine residues between the human and bovine forms of factor Va, 
both of which inhibit factor V endocytosis. Therefore, if possible, further studies with this 
antibody may be useful to identify what regions of factor V mediate its endocytosis by 
megakaryocytes. Furthermore, anti-factor V #2 is directed toward a 
nonconformational/linear epitope, which should be easier to map compared to 
conformational/nonlinear epitopes.  
 In studies not presented in this thesis, the arginine-specific reagent, 
phenylgloyoxal, was used in a single attempt to modify factor V for a protein 
modification approach. Mass spectrometry analysis was unable to identify any modified 
Arg residues indicating that factor V was not modified by this reagent. Due to time 
constraints, this approach was abandoned. Future experiments could focus on optimizing 
the conditions for protein labeling with this reagent, and the solid phase binding assay 
developed in this study could be used to analyze the reactivity of the modified protein 
with E9. Additionally, other modifying reagents, specified in Chapter 2, could be 
employed in the event that modification with phenylglyoxal is ultimately unsuccessful. In 
addition, H/D exchange, which targets the backbone amide hydrogens for modification 
could also be performed. 
 If the experiments described above are not successful, then alternative approaches 
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would have to be employed. Though time intensive, X-ray crystallography could be used 
to determine the structure of the immunocomplex of the isolated light chain of factor V 
(Nesheim, Katzmann et al. 1981) and the Fab fragment of E9. Alternatively, fragments of 
the factor V light chain could be crystallized with the antibody in the event that we are 
able to generate fragments of the factor V light chain that can be isolated under non-
denaturing conditions. If successful, this approach would allow for the visualization of 
the contacting residues at the interface of the immunocomplex, which would include the 
E9 epitope.  
  Alternatively, bioinformatics could be performed as a number of computational 
tools for epitope mapping exist. When the three dimensional structure of the antigen is 
known, the epitope could potentially be predicted computationally. The 2.8 Å crystal 
structure of APC-inactivated bovine factor Va was solved by Adams et al. (Adams, 
Hockin et al. 2004), and is readily available in the Protein Data Bank (PDB ID: 1SDD). 
 Epitope mapping antibodies that target conformational epitopes is a challenging 
and time consuming endeavor. Extensive work was done in epitope mapping the E9 
antibody, and although additional work remains to be done, the data presented in this 
study present a solid framework that can be used for future studies aimed at defining this 
antibody’s epitope. Knowledge of the E9 epitope would provide information regarding 
the cellular process responsible for the generation of platelet-derived factor V, and would 
specifically contribute to the understanding of the mechanism of the megakaryocyte two 
receptor system. Furthermore, given that E9 is utilized primarily in isolating factor V 
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from both human and bovine plasma, defining its epitope would prove useful for other 
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